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ABSTRACT  
   
Researchers in the twentieth and twenty-first centuries identify the study of the 
intrinsic and external factors that influence human aging as senescence. A commonly 
held belief in the year 2015 is that at least some kinds of cells can replicate over long 
periods or even indefinitely, thereby meaning the cell does not undergo senescence (also 
known as replicative senescence) and is considered immortal. This study aims to provide 
information to answer the following question: While some scientists claim they can 
indefinitely culture a stem cell line in vitro, what are the consequences of those culturing 
practices? An analysis of a cluster of articles from the Embryo Project Encyclopedia 
provides information to suggest possible solutions to some potential problems in cell 
culturing, recognition of benefits for existing or historical culturing practices, and 
identification of gaps in scientific knowledge that warrant further research. Recent 
research suggests that hESCs, and immortalized cell lines in general, do not escape the 
effects of senescence. While there exists a constant change in the practices of cell 
culturing, a large portion of scientists still rely on practices established before modern 
senescence research: research that seems to suggest that cultured hESCs, among other 
immortal cell lines, are not truly immortal. 
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CHAPTER 1 
INTRODUCTION 
One objective of medical science is to prolong human life. In order to understand 
how science can extend a human life, it is helpful to understand what scientists 
commonly think are causes of human aging, and subsequently death. Researchers in the 
twentieth and twenty-first centuries identify the study of the intrinsic and external factors 
that influence human aging as senescence. Much of the scientific research of senescence 
focuses on the intrinsic and external factors of the cell in particular, as it is the basic unit 
of biological life forms. Therefore, cellular senescence (also known as cytogerontology 
during the 1970s and early 80s), refers to factors that cause cells to age, particularly 
relating to the capacity of a cell to replicate (Campisi).   
A commonly held belief in the year 2015 is that at least some kinds of cells can 
replicate over long periods or even indefinitely, thereby meaning the cell does not 
undergo senescence (also known as replicative senescence) and is considered immortal. 
A cell line that does not undergo senescence is called an immortalized cell line. 
Immortalized cell lines can include stem cells, as well as cancer cells. Immortalized cells 
that acquire replicative immortality through various mutations are called cancer cells, 
whereas immortalized cells that are a normal part of development are called stem cells. 
Scientists define stem cells based on the following criteria (NIH):  
1. Stem cells can renew themselves for prolonged periods through cellular division 
(self-renewal) 
2. Stem cells give rise to other cell types in the body (differentiation) 
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Stem cells are very alluring to researchers because of their potential applications in 
medicine to regenerate damaged tissues and slow the human aging process. 
Scientists classify stem cells into two categories: adult and embryonic. The most 
sought after stem cells are human embryonic stem cells (hESC), or cells from the inner 
cell mass of a blastocyst of a human pre-implantation embryo. Adult stem cells are 
typically limited to becoming only a few cell types whereas embryonic stem cells from 
the blastocyst are capable of becoming all cell types, except for extra-embryonic 
structures such as the placenta. Extra-embryonic structures are derived from cells as part 
of the morula, which scientists consider “totipotent”, or capable of becoming all cell 
types. Researchers call hESCs “pluripotent”.  Some scientists claim that hESCs have 
“basically indefinite proliferative capacity, [and] they lend themselves as practically 
inexhaustible resource” (Zachar).  
While scientists claim they can indefinitely culture a stem cell line in vitro, what 
are the consequences of those culturing practices? To understand such a question, and the 
modern definition of senescence and how it applies to immortal cell lines, it is useful to 
examine what scientists thought about cells and aging in decades past. For the purposes 
of this research, the historical background will be limited within the timeframe of the late 
19th century to the year 2015. A series of articles published in The Embryo Project 
Encyclopedia can serve as a tool to help understand what scientists thought about aging 
and cells in the past.  
The Embryo Project Encyclopedia is a part of the Embryo Project at Arizona 
State University. The Embryo Project Encyclopedia houses a collection of research 
“related to the sciences of embryology, development, and reproductive medicine, their 
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legal, ethical and social contexts, and histories of those sciences and contexts” (The 
Embryo Project). Though the Embryo Project Encyclopedia is a collection of individual, 
independent articles, inquiring minds can examine clusters of topically related articles to 
provide insights into why scientists might think the way they do, or why they might 
conduct certain research. This method of examining clusters of articles seems particularly 
useful to determine how modern scientists could view research related to stem cells and 
aging. With the aid of Embryo Project Encyclopedia articles, this thesis aims to provide 
information to help answer the following question: What are some of the common 
techniques used to acquire stem cells and what happens to immortal cell lines 
(particularly embryonic stem cell lines) when scientists culture them indefinitely in vitro? 
Chapters 2 through 5 highlight multiple methods of acquiring cell populations, 
including immortal cell populations. The research is grouped both chronologically and 
contextually, with related articles clustered together in the same chapter. Each chapter 
begins with a brief synopsis of related Embryo Project Encyclopedia articles, as well as 
relevant historical information. Embryo Project Encyclopedia article titles are followed 
by citations to the corresponding article. For convenience, the full articles are included in 
this thesis. More specifically, chapter 2 examines general senescence history and 
information, chapter 3 examines research on telomeres and telomerase, chapter 4 
examines research on cloning, and chapter 5 examines a modern cell culturing practice.  
Chapter 6 attempts to give answers to the driving question of the thesis. The 
answers can come in part from examining the work of scientists from the 19th to 21st 
centuries. Such an examination will provide recognition of possible benefits and 
detriments for existing or historical culturing practices, identification of potential gaps in 
  4 
scientific knowledge that warrant further research, and the formulation of possible 
solutions to potential problems.
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CHAPTER 2 
IMMORTAL, MORTAL, OR BOTH? – GENERAL SENESCENCE HISTORY AND 
INFORMATION 
Historians often accredit August Weismann as one of the earliest to identify a 
possible link between cell biology and aging in the late nineteenth century. In search of 
an evolutionary explanation for aging, Weismann theorized that an organism’s lifespan 
was determined by the number of generations a cell could produce. However, Weismann 
was unable to provide substantial empirical evidence to support his claims (Kirkwood).  
Weismann was not the only researcher in the early 1900s to explore the idea of 
aging in cells. Charles Sedgewick Minot also studied senescence in his work with 
embryos and human anatomy. In his 1908 book, Minot defined senescence as a decrease 
of power of cell growth, which occurs every time a cell divides.  
In 1912, the Nobel Laureate Alexis Carrel published an experiment that gave 
evidence to suggest that the power of cell growth does not diminish with time when 
cultivated in vitro, or outside of the body. Immortality, according to Carrel, was an 
intrinsic characteristic of all cells. With further research, Carrel claimed that “permanent 
life” in vitro was possible if researchers paid special attention to maintain glassware, and 
if correct nutrients were given to the cultured cells (Carrel, Jiang, Landecker). Though 
Carrel’s hypothesis suggested immortality as an internal factor in cells, the causes of 
aging were external. Once Carrel published and propagated his research, Weismann and 
Minot’s theories were quickly overshadowed. For many years, the majority of biologists 
considered Carrel’s experiments and his interpretations as fact, despite repeated failures 
in attempts to reproduce Carrel’s results. 
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As a result of Carrel’s work, other scientists attempted to establish “immortal” 
cell lines, with hopes of achieving immortality for human cells. Among the eager 
scientists was George Gey, at John’s Hopkins University. In 1951, Gey obtained and 
cultured cells from Henrietta Lacks, a woman suffering from cervical cancer. Scientists 
named the cells HeLa, after the patient’s name. His team dubbed the resulting cell 
cultures immortal in the same way that Alexis Carrel’s cell lines were immortal, as they 
were able to propagate the human cell line for over a year without any signs that the cells 
were subject to senescence (Scherer). HeLa cells continue to be widely used in research 
to develop vaccines and study human disease.  
In 1961, a scientist named Leonard Hayflick observed a phenomenon in human 
cells he cultured in vitro. He noted that the cells ceased replication after forty to sixty 
divisions, or cell population doublings (Hayflick). Such an observation was contradictory 
to Carrel’s commonly accepted notion of cell biology, and cell cultures such as HeLa. 
Hayflick experimented further in 1965, and concluded that Carrel’s theory of senescence 
was incorrect, as it appeared that some cells were not capable of replicating indefinitely. 
He also hypothesized that there was a factor within cells that caused the cessation in 
replication. Hayflick rigorously researched and reported his findings, and soon Carrel’s 
hypothesis of universal cell immortality was disregarded. As a result of Hayflick’s 
experiments, Sir Macfarlane Burnet named the limited capacity for cellular division the 
Hayflick Limit in 1974.  
During the 1950s, scientists were also researching the causes of cell death. In 
1951, Alfred Glücksmann observed a phenomenon of cell death in embryos, which he 
claimed was necessary for tissue and organ formation. It was a phenomenon that John 
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Kerr and his colleagues at the University of Aberdeen, in Aberdeen, Scotland would call 
apoptosis in 1972.  
To begin understanding the mechanics of life, scientists often asked why or how 
life ended. The following articles from the Embryo Project Encyclopedia are glimpses 
into how scientists in the 19th and 20th centuries viewed death, particularly in terms of 
the death and lifespan of cells. 
 
Apoptosis and its Role in Embryonic Development 
 
Bartlett, Zane. “Apoptosis and its Role in Embryonic Development”. (Citation pending publication in the 
Embryo Project Encyclopedia)  
 
Apoptosis is an essential mechanism in embryonic development and it is a form 
of programmed cell death, which occurs naturally in organisms. The process of apoptosis 
is different from cell necrosis, which usually occurs uncontrolled after infection or 
specific trauma. As rapid cell proliferation occurs during development, certain cells 
undergo apoptosis, which is necessary for many stages in development, including neural 
development, reduction in oocytes at birth, as well as the shaping of digits and vestigial 
organs in humans and other animals (Barres, Jacobson, Reynaud).  Karl Vogt first 
observed the phenomenon of apoptosis in 1842 while studying the midwife toad (Alytes 
obstetricans) in Neuchâtel, Switzerland, but little effort occurred to understand it for 
about a century. Alfred Glücksmann researched the phenomenon in 1951 while working 
at the Strangeways Research Laboratory in Cambridge, England, and published a review, 
claiming it was important to embryological development. In 1972, John Kerr and his 
colleagues at the University of Aberdeen, in Aberdeen, Scotland, claimed that apoptosis 
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was the same process in body cells, called somatic cells, as it was during development of 
embryological cells. Kerr and his colleagues coined the term apoptosis, after the Greek 
words apo and ptosis, which translates to falling, or dropping off. Sydney Brenner, H. 
Robert Horvitz and John E. Sulston received the Nobel Prize in Physiology or Medicine 
in 2002 for their work on the genetic regulation of organ development and programmed 
cell death. As researchers continue to map out the processes of cell lineages before and 
after embryonic development, they may also learn new ways to reduce or promote cell 
death, which can be important in preventing diseases such as Alzheimer’s or cancer. 
The phenomenon of apoptosis was first observed by Karl Vogt in in Neuchâtel, 
Switzerland, in 1842, however Vogt did not call the phenomenon apoptosis. Vogt noticed 
in midwife toad embryos that cells in the notochord, a cartilaginous skeletal structure, 
disappeared and were replaced by cells of the vertebrae (Clark). Though Vogt 
documented the disappearance of cells during development, he did not focus his research 
on the disappearances (Vogt). Because of that lack of focus, the phenomenon was not 
given very much attention until 1885 when Walther Flemming, who worked at the 
University of Kiel, Kiel, Germany, used more advanced staining techniques of the cell 
nucleus to observe what he called chromatolysis, the distinct diminishing of nuclear 
material in dying cells (Flemming). Chromatolysis is part of the process of apoptosis, but 
Flemming’s research was forgotten until the developmental biologist, Alfred 
Glücksmann, published a review on cell death literature in 1951 while working at the 
Strangeways Research Laboratory in Cambridge, England (Peter).  
Glücksmann’s embryological review on cell death influenced general acceptance 
of apoptosis as an essential part of embryonic development. He hypothesized that for an 
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organism to grow and develop, cell death must occur. At the time of Glücksmann’s 
review, many scientists mistook dead cells observed under a microscope as metabolic 
byproducts of cells undergoing mitosis, or cellular replication. Glücksmann attempted to 
dispel these beliefs by presenting evidence from past embryological research that pointed 
to planned cell death as an aspect of normal development. Glücksmann’s findings went 
largely unnoticed for a period of over twenty years. However, John Kerr, Andrew Wyllie, 
and Alastair Currie, pathologists working at the University of Aberdeen, Aberdeen, 
Scotland, referenced Glücksmann’s review as motivation to develop their own research in 
1972. 
Kerr had first studied cell death in 1965 when he noticed atrophy, or shrinkage, in 
rat liver cells under an electron microscope. Kerr noticed that the shrinkage was distinct 
from necrosis due to trauma, which normally causes the cell to rupture and release its 
contents, so Kerr decided to study it further with Wyllie and Currie. They noticed 
common patterns involved in cell death, as recorded in previous experiments and 
reviews, including Glücksmann’s work. Kerr and his team felt there should be a specific 
name for what they considered to be programmed cell death, a concept they understood 
from research conducted by Richard Lockshin and Carroll Williams at St. John’s 
University, New York City, New York, in 1964. Kerr and his colleagues coined the term 
for the new form of programmed cell death, apoptosis. They claimed that cell death from 
apoptosis was not accidental, and that it followed the same pattern in developing cells as 
it did in developed cells. Kerr and his team’s work unified years of embryological 
research conducted by scientists like Vogt, Flemming, and Glücksmann. Kerr and 
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colleagues brought the idea of apoptosis to greater scientific attention when they 
published their research in 1972. 
After Kerr, Wyllie, and Currie’s research, scientists understood that apoptosis 
followed specific steps, which scientists independently verified. First, cells undergoing 
apoptosis begin to shrink in size and lose physical connections with neighboring cells. 
Second, the chromatin, which is the combination of DNA and protein within the cell 
nucleus, condenses and enzymes begin to fragment the chromatin within the cell. Third, 
the cell membrane bulges irregularly, or blebs. Fourth, the nucleus collapses and breaks 
into fragments containing pieces of chromatin, while the cell continues to bleb. Fifth, the 
cell breaks into several smaller membrane bodies that contain various cellular fragments, 
called apoptotic bodies. Lastly, white blood cells (phagocytes) or neighboring cells 
engulf the apoptotic bodies and break them down. The organism suffers no major injury 
as a result.  
After Kerr, Wyllie, and Currie’s findings, scientists accepted apoptosis as a 
mechanism in cellular development and began to study its significance in development 
and disease. Some of those scientists were Sydney Brenner, Robert Horvitz, and John 
Sulston, who researched at Berkeley, California, Cambridge, Massachusetts, and 
Cambridge, England, respectively. They conducted much of their early research on the 
nematode, Caenorhabditis elegans (C. elegans) in the 1970s, and continued through the 
late twentieth century. Through diagrams of cell lineages and careful documentation, 
Brenner, Horvitz and Sulston predicted when cell death would occur, and they identified 
some of the genes involved in the regulation of cell death. Horvitz, in particular, noted in 
his research that C. elegans neurological development included a large amount of 
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apoptosis, with 105 of the 131 programmed cell deaths occurring in neural cells. Brenner, 
Horvitz, and Sulston received the Nobel Prize in Physiology or Medicine in 2002 for 
their work in genetic regulation of organ development and programmed cell death.  
Research conducted since Brenner, Horvitz, and Sulston published their findings 
on C. elegans continues to reinforce to the idea that programmed cell death through 
apoptosis is essential for development in animals. In 1993, scientists working with 
Horvitz found that a gene in mice was very similar to a gene in C. elegans, which coded 
for an enzyme that caused cell death during development. The research provided 
evidence to believe that the process involved with apoptosis in C. elegans is the same in 
mammals.    
In 1997, Michael Jacobson and researchers at the MRC Lab of Molecular Biology 
in Cambridge, England, outlined the importance of cell death in animals in the article 
“Programmed cell death in animal Development”. They claimed that the primary 
functions of apoptosis are to sculpt the organism by deleting unwanted structures, 
controlling cell numbers, and eliminating nonfunctional, harmful, abnormal, or misplaced 
cells. Absence of apoptosis can include malformations of digits, decreased neurological 
function, malformations of the heart, or even cancer. For example, soft tissue cells 
between the fingers and toes undergo apoptosis in order to separate the digits from each 
other during development. The proper formation of heart loops also relies on the process 
of apoptosis to correctly shape the heart. 
Gary Wessel, in his article "The apoptotic oocyte", provides research about the 
role of apoptosis in human females. Human female oocytes undergo apoptosis during 
development and after birth. Scientists estimate there are seven to eight million oocytes 
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formed in the fetus, which are reduced to about 100,000 oocytes at birth, and then only a 
few hundred at the onset of menopause (Wessel).  
Jacobson and his colleagues claimed that apoptosis occurs not only during 
embryonic development, but also after birth (Jacobson). In humans for example, brain 
cells undergo apoptosis prior to and following birth to eliminate excess brain cells and 
streamline nerve impulses. Apoptosis also occurs in some cells that the body identifies as 
cancerous in order to prevent the spread of the cancer and safely kill the cancerous cell. 
However, unregulated apoptosis can cause disorders, such as amyotrophic lateral 
sclerosis, which is a motor neuron disease, and Alzheimer’s disease, which affects the 
brain, due to cell death in crucial memory areas of the brain (Honig).  
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Leonard Hayflick (1928- )  
 
Bartlett, Zane, "Leonard Hayflick (1928- )". Embryo Project Encyclopedia (2014-07-20). ISSN: 1940-5030 
http://embryo.asu.edu/handle/10776/8042.  
 
During the twentieth and twenty-first centuries in the United States, Leonard 
Hayflick studied the processes by which cells age. In 1961 at the Wistar Institute in the 
US, Hayflick researched a phenomenon later called the Hayflick Limit, or the claim that 
normal human cells can only divide forty to sixty times before they cannot divide any 
further. Researchers later found that the cause of the Hayflick Limit is the shortening of 
telomeres, or portions of DNA at the ends of chromosomes that slowly degrade as cells 
replicate. Hayflick used his research on normal embryonic cells to develop a vaccine for 
polio, and from Hayflick’s published directions, scientists developed vaccines for rubella, 
rabies, adenovirus, measles, chickenpox and shingles. 
Hayflick was born on 20 May 1928 in Philadelphia, Pennsylvania, to Edna 
Hayflick and Nathan Hayflick. His father designed prosthetics for dental patients. When 
Hayflick was nine, one of his uncles bought him a chemistry set. Hayflick’s parents 
allowed him to build a laboratory in the basement of their home, where he performed 
biology and chemistry experiments. Hayflick attended John Bartram High School in 
Philadelphia. During some of his first chemistry lectures, Hayflick corrected his teacher, 
who then allowed him to help in the chemical stockroom, where Hayflick acquired more 
chemicals for his studies. 
Hayflick enrolled in the University of Pennsylvania in Philadelphia in January 
1946 but postponed his studies for military service. After he served in the military for 
  15 
eighteen months from 1946 to 1948, Hayflick received a four-year scholarship through 
the GI Bill, a US federal government initiative to help veterans return to civilian life after 
World War II. Hayflick studied microbiology at the University of Pennsylvania and 
graduated in 1951. After graduating, Hayflick took a job as a research assistant in 
bacteriology in 1951 with Merck, Sharp, and Dohme laboratories in North Wales, 
Pennsylvania. According to Hayflick, he felt that graduate school would have been too 
difficult for him until he met a friend who studied bacteria species in the 
genus Mycoplasma, which are bacteria often involved in pneumonia and other diseases. 
Those studies convinced him to return to the University of Pennsylvania to receive a 
Master’s degree for his study of Mycoplasma. While at the University of Pennsylvania, 
Hayflick also met Ruth Heckler, whom he married and with whom he had five children. 
As a Master’s student, Hayflick’s mentor Warren Stinebring sent him to the 
Wistar Institute to research an infection in a rat colony. Hayflick showed that the 
infection was due to Mycoplasmas. Hayflick received a Master’s degree in medical 
microbiology in 1953. He won a fellowship to a PhD program, in which he continued his 
research. Hayflick received a PhD in medical microbiology and chemistry in 1956 from 
the University of Pennsylvania. 
In 1956, Hayflick moved to the department of microbiology at the University of 
Texas in Galveston, Texas. He worked with cell culturist Charles Pomerat. With Pomerat, 
Hayflick learned techniques to produce cell cultures, or populations of cells living in 
controlled conditions. When the fellowship at the University of Texas expired, Hayflick 
applied for work elsewhere. In 1958, the new director of the Wistar Institute, Hilary 
Koprowski, offered Hayflick a job to culture cells for the other scientists at the institute. 
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Hayflick accepted the position and moved back to Philadelphia to work at the Wistar 
Institute. 
Since the early 1900s, a predominant theory of cells in culture assumed that cells 
could multiply and grow forever. This assumption relied on the early twentieth century 
studies of Alexis Carrel, a physician in France, whose work with chick hearts had 
convinced many that all cells were immortal. If cells failed to grow in the lab, researchers 
attributed the failure to unknown nutritional conditions, to technicians incorrectly 
handling the cells, or to contaminations in the glassware. 
At the Wistar Institute in 1958, Hayflick began to study whether or not viruses 
could cause cancers in humans. Hayflick cultured human cancer cells. He aimed to 
extract from them viruses, hypothesized to cause cancer, that he could isolate by 
introducing them into normal cells in culture. For this study, he needed to grow normal 
human cells not containing any viruses in a lab. Hayflick used fetal human lung cells 
because, compared to adult cells, they had a lower chance of containing viruses, and lung 
tissue allowed for the formation of fibroblasts, or structural cells in the body. 
While he cultured twenty-five strains of fetal cells, Hayflick noticed that some of 
the cultures stopped dividing after about 50 cell population doublings. The cells were not 
dead, as they continued metabolizing, but the cells did not divide. Hayflick published an 
article in 1961 detailing the results of these cell cultures titled "The serial cultivation of 
human diploid cell strains." 
In 1965, Hayflick published "The limited in vitro lifetime of human diploid cell 
strains." In this article, Hayflick notes that adult cells divide fewer times than do fetal 
cells, and that the cause of this limited cell division isn't caused by a virus, bacteria, or 
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accounted for by error. Hayflick hypothesized in his article that cellular aging could 
result from one or many targets or substances of cellular damage and that the cells could 
hold intrinsic factors that determine aging. 
At the time of the 1965 experiment, Hayflick had established a cell culture, the 
WI-38 strain, with fetal cells that Hayflick had acquired from Sweden. Hayflick shipped 
these WI-38 cultures to many other scientists, including Stanley Plotkin at the Wistar 
Institute, where the cells were later used for rubella vaccines. WI-38 cells began to be in 
high demand during the 1960s. 
Despite Hayflick’s recognition for the WI-38 cultures, he remained in the same 
associate position at the Wistar Institute, which was partially funded by the US National 
Institutes of Health (NIH) headquartered in Bethesda, Maryland. Koprowski had also 
created a guaranteed deal with SmithKline Beckman in the US and the Burroughs 
Wellcome Company in the UK to purchase WI-38 cultures, as well as the cell-culture 
technology that Hayflick created to produce a polio vaccine with the live, attenuated 
virus. Hayflick later said that he was unhappy with Koprowski’s decision to sell the cells 
for profit. 
In 1968, Hayflick accepted a position as a professor of medical microbiology 
at Stanford University in Stanford, California. In Janurary of 1968, Hayflick met with 
Kaprowski and representatives of the NIH and American Type Culture Collection 
(ATCC), based in Rockville, Maryland, to discuss what would occur with the remaining 
containers of WI-38 cells, as Hayflick would soon be changing jobs. Those present at the 
meeting agreed to allow Hayflick ten containers of the WI-38 cells, with ten of the 
remaining WI-38 cultures placed at the Wistar Institute and the rest in the care of the 
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ATCC as property of the NIH. However, the NIH claimed that it owned the cells and that 
only it could distribute and sell the cells through the ATCC. Hayflick claimed to have 
title to own the cells, and that the estate of the fetus also had an interest in the cells. 
Hayflick reported that he felt a sense of injustice, and he went to the Wistar 
Institute and took all of the WI-38 samples before leaving for California. He sent these 
cultures to scientists for the same price that the ATCC would have charged researchers 
for shipping the cells, and he saved that money into a special account until a further 
decision on ownership of the cells could be determined. In the spring of 1975, Hayflick 
brought the issue of ownership to the NIH in hopes of settling who owned the cells. Later 
that year, NIH accountants and some US Department of Health, Education, and Welfare 
(DHEW) employees investigated Hayflick. Under the 1966 US Freedom of Information 
Act, the NIH gave the accountant’s report to journalists who published it in March of 
1976. The report claimed that Hayflick had stolen and sold property of the United States 
Government, and that he had mishandled the cells. 
Hayflick sued the NIH in 1975 to prevent the release of the report and to gain the 
title to the WI-38 cells, arguing that the report violated the 1974 US Privacy Act. A 
California court denied a motion for preliminary injunction of the reports, and Hayflick 
followed with an appeal in 1978, after the reports were released. The US Ninth District 
Court of Appeals affirmed the previous decision, and they dismissed the appeal. With 
tension growing from the release of the reports, Hayflick left his job at Stanford in what 
he called a protest to the behavior of the university leadership, and the NIH confiscated 
his WI-38 cell cultures while Hayflick attended a conference. The issue as to who had 
title to the WI-38 cells remained unresolved. 
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In late 1976, Hayflick accepted a position as a senior researcher at Children’s 
Hospital Medical Center in Oakland, California. In 1977, the NIH accepted Hayflick’s 
application for a grant for some money as well as for WI-38 cells. Hayflick did not 
receive that grant or any WI-38 cells until January of 1981. Hayflick continued to ask for 
the title of the WI-38 cells, and an out-of court settlement was offered by the US Justice 
Department, the US Food and Drug Administration (FDA), NIH, and the DHEW in the 
summer of 1981. After some modifications, Hayflick settled with the FDA, the NIH, and 
the DHEW, and he received title to six of the original containers of WI-38 cells. He also 
received the ability to use the money, plus interest, from an escrow account. He had 
opened the account at the start of the suit and had deposited in it the money he’d received 
from distributing the WI-38 cells while at Stanford. Hayflick later said that all of that 
money paid litigation fees. After the settlement, eighty-five scientists filed a letter in 
favor of Hayflick in the journal, Science. Hayflick and others claimed that it was through 
his efforts in asking for the title to the WI-38 cells that helped US policy to evolve, and to 
allow research institutions and scientists to receive title to new life forms, even when the 
research is federally funded. 
In his 1974 work, Intrinsic Mutagenesis: a Genetic Approach to Ageing, the 
Nobel Prize Laureate Frank MacFarlane Burnet called Hayflick’s account of cellular 
aging The Hayflick Limit. In 1981, Hayflick became director of the Center for 
Gerontological Studies in Gainesville, Florida, as well as professor at the University of 
Florida in Gainesville. In 1982, Hayflick became president of the Gerontological Society 
of America in Washington D.C. 
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In 1988, Hayflick became a professor at the University of California in San 
Francisco, California. In 1994, he published a book titled How and Why We Age. 
Hayflick received greater than twenty-five awards, authored greater than two-hundred 
and fifty scientific works, and has participated in various editing, government, and 
medical boards and councils. As of 2014, Hayflick serves on various scientific 
committees and is writing an autobiography while living in California. 
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The Hayflick Limit 
Bartlett, Zane, "The Hayflick Limit". Embryo Project Encyclopedia (2014-11-14). ISSN: 1940-5030 
http://embryo.asu.edu/handle/10776/8237. 
The Hayflick Limit is a concept that helps to explain the mechanisms 
behind cellular aging. The concept states that a normal human cell can only replicate and 
divide forty to sixty times before it cannot divide anymore, and will break down by 
programmed cell death or apoptosis. The concept of the Hayflick Limit revised Alexis 
Carrel's earlier theory, which stated that cells can replicate themselves infinitely. Leonard 
Hayflick developed the concept while at the Wistar Institute in Philadelphia, 
Pennsylvania, in 1965. In his 1974 book Intrinsic Mutagenesis, Frank Macfarlane Burnet 
named the concept after Hayflick. The concept of the Hayflick Limit helped scientists 
study the effects of cellular aging on human populations from embryonic development to 
death, including the discovery of the effects of shortening repetitive sequences of DNA, 
called telomeres, on the ends of chromosomes. Elizabeth Blackburn, Jack Szostak and 
Carol Greider received the Nobel Prize in Physiology or Medicine in 2009 for their work 
on genetic structures related to the Hayflick Limit. 
Carrel, a surgeon in the early twentieth century France working on cultures 
of chick heart tissue, argued that cells can infinitely replicate. Carrel claimed that he had 
been able to have those heart cells replicate in culture for greater than twenty years. His 
experiments on chick heart tissue supported the theory of infinite replication. Scientists 
tried to replicate Carrel's work many times, but these repeated experiments never 
confirmed Carrel's findings. 
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Hayflick worked for the Wistar Institute in 1961 where he observed that human 
cells do not replicate infinitely. Hayflick and Paul Moorhead described the phenomenon 
in a paper titled "The serial cultivation of human diploid cell strains." Hayflick's job at 
the Wistar Institute was to provide cell cultures to scientists who conducted experiments 
at the Institute, but Hayflick pursued his own research on the effects of viruses in cells. In 
1965, Hayflick further detailed the concept of the Hayflick Limit in cells in a paper titled 
"The limited in vitro lifetime of human diploid cell strains." 
In that article, Hayflick concluded that a cell could complete mitosis, or cellular 
duplication and division, only forty to sixty times before undergoing apoptosis and 
subsequent death. The conclusion held for many cell types, whether they were adult cells 
or fetal cells. Hayflick hypothesized that the limited replicative capability of the cell 
related to aging in cells and, consequently, to human aging. 
The publication of Hayflick's experiments disconfirmed Carrel's theory about 
indefinite cellular replication. Some, such as Harry Rubin at the University of California 
at Berkeley in Berkeley, California, argued in the 1990s that the Hayflick Limit pertained 
only to damaged cells. Rubin suggested that cellular damage could result from the cells 
being in an environment that differed from their original environment in the body, or 
when researchers subjected the cells to laboratory practices. 
Regardless of the criticism, other scientists used Hayflick's theory in support of 
further studies about cellular aging, especially with research in telomeres, which are 
repetitive sequences of DNA at the ends of chromosomes. Telomeres protect the 
chromosome from folding in on itself, and they decrease mutations in the DNA. In 1973, 
Alexey Olovnikov, in Russia, applied Hayflick's theories of cell death to his studies of 
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the ends of chromosomes that did not replicate themselves during mitosis. He said that 
the process of cell division ends once the cell cannot replicate the ends of their 
chromosomes. 
Although Olovnikov applied Hayflick's theory to his experiments, Olovnikov did 
not name Hayflick's theory. One year later in 1974, Burnet coined the term Hayflick 
Limit in his work, Intrinsic Mutagenesis. Burnet's work focused on the claim that age 
was intrinsic to the cells in each species and that they followed the Hayflick Limit, thus 
establishing a programmed age in which an organism would die. Elizabeth H. Blackburn 
at the University of California San Francisco in San Francisco, California, and Jack W. 
Szostak at Harvard Medical School in Boston, Massachusetts, also applied Hayflick's 
theory of cellular aging to their research on the structures of telomeres in 1982, when 
they cloned and isolated telomeres. In 1989, Greider, and Blackburn further developed 
the theory of cellular aging to discover the enzyme that replicates telomeres, called 
telomerase. Greider and Blackburn found that the presence of telomerase helps cells 
escape programmed cell death. 
With theories about the biological mechanisms behind aging, scientists expected 
that they could create a cure for aging. Hayflick helped found the National Institute on 
Aging in Bethesda, Maryland, in 1974, a branch of the National Institutes of Health in the 
United States. In 1982, Hayflick also became the president of the Gerontological Society 
of America, founded in 1945 in New York, New York. Hayflick role helped to spread the 
theory of the Hayflick Limit and to further counter the theory of cellular immortality as 
established by Carrel. 
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In 2009, Blackburn and Szostak received the Nobel Prize in Physiology or Medicine for 
their work on telomerase, in which the Hayflick Limit played an essential role. 
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Biotechnology 16 (1998): 396–7. 
 
Shay, Jerry W., and Woodring E. Wright "Hayflick, his limit, and cellular 
ageing". Nature Reviews Molecular Cell Biology 1 (2000): 72–6. 
 
Szostak, Jack W. and Elizabeth H. Blackburn. "Cloning yeast telomeres on linear 
plasmid vectors." Cell 29 (1982): 245–55. 
 
Leonard Hayflick’s 1964 Experiment, “The Limited In Vitro Lifetime of Human 
Diploid Cell Strains” 
Bartlett, Zane. “Leonard Hayflick’s 1964 Experiment, ‘The limited In Vitro Lifetime of Human Diploid 
Cell Strains’”. (Citation pending publication in the Embryo Project Encyclopedia) 
“The Limited In Vitro Lifetime of Human Diploid Cell Strains” reports on a 
scientific experiment published in Experimental Cell Research on 4 May 1964. The 
experiment details information on the cell’s limited ability for cellular division. Leonard 
Hayflick performed the experiment with WI-38 fetal lung cells, named after the Wistar 
Institute, in Philadelphia, Pennsylvania, where Hayflick worked. The Nobel Prize 
Laureate, Sir Frank MacFarlane Burnet, later called the limit in capacity for cellular 
division the Hayflick Limit in his work, Intrinsic Mutagenesis: a Genetic Approach to 
Ageing, published in 1974 (Web of Stories, Burnet). In the experiment, Hayflick refutes 
Alexis Carrel’s hypothesis that cells could be transplanted and multiplied indefinitely (by 
a process called sub-culturing) from a single parent cell line. The experiment helped 
scientists gain greater insight into cellular and human aging, as well as the implications of 
this form of cellular aging for understanding embryonic stem cells.  
Leonard Hayflick is the sole experimenter of the “Limited In Vitro Lifetime” 
experiment. Hayflick received a PhD in Medical Microbiology and Chemistry in 1956 
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from the University of Pennsylvania in Philadelphia, Pennsylvania, (Hayflick) and 
worked at the Wistar Institute in 1964, where he conducted the experiment. His primary 
role at the Wistar Institute was to provide cell cultures to the scientists there who were 
performing research in various areas of microbiology (Jiang). While providing cell 
cultures to other researchers, Hayflick worked on his own research on viruses and how 
they can cause cancer in human cells. 
Hayflick’s motivation for his 1964 experiment arose in response to phenomena 
observed in a previous experiment, “The serial cultivation of human diploid cell strains,” 
conducted with Paul Moorehead in 1961 (Hayflick). They were trying to find better and 
more effective ways to cultivate cell populations for future experiments. In the process of 
culturing twenty-five strains of fetal lung cells for his experiment with Moorhead, 
Hayflick noticed that some of the cultures had completely stopped dividing, although 
they were still metabolizing. Hayflick found it odd that the cells stopped dividing in older 
cell populations, despite the fact that the same technician conducted the procedure using 
the same culture media and the same glassware (Web of Stories). Hayflick’s observations 
contradicted Carrel’s theory that cells would continue to replicate indefinitely. At the 
time of the experiment’s publication in 1961, Hayflick hypothesized that cells had 
intrinsic factors that determined aging. However, he and Moorhead were not able to rule 
out the possibility that viruses interfered with the functioning of the cells and caused the 
cells to stop dividing.  
In his 1964 experiment, Hayflick decided to further examine the mechanisms that 
could cause the fetal cells to stop dividing. He created subcultures from fetal lung cell 
lines and adult lung tissue and named the cultures after the Wistar Institute (Hayflick) and 
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by number order. Hayflick cultured fetal lung tissue received from male and female 
fetuses and he named the male derived cells WI-26 and the female derived cells WI-38 
and WI-44. He extracted the fetal lung tissue from aborted fetuses at about three months’ 
gestation (Hayflick), and he generated the adult strains from lung tissue of dead adults, 
and froze both of them in a container with liquid nitrogen in order to preserve them. Each 
subculture split in a two-to-one ratio, which means that each cell in the samples divided 
once, producing two more cells.  
Hayflick’s results pointed to the fact that in a two-to-one split ratio, the average 
number of times a fetal cell could divide was between forty to sixty times. In adult cells, 
the average number of times a cell would multiply was twenty after cultivation. That data 
suggested that numerous cell duplications had already occurred in adult cells, and that the 
number of duplications in the lab setting were less in comparison to the fetal cell strains. 
In the experiment, he called the phase when the cell ceases to divide phase III, with phase 
I and II being periods where a cell rapidly proliferates (Hayflick). 
Hayflick was curious to see whether fifty was the average number of divisions for 
every fetal cell within the same population or if it was just a randomly occurring number. 
To test his hypothesis, Hayflick randomly selected and cloned three samples of the fetal 
cell line, WI-38, and recorded when each population stopped dividing. The resulting 
range for each clone was from fifty to fifty-four. That data lead Hayflick to believe the 
amount of times a cell can double is determined by an internal factor within the cell, 
which Hayflick thought was some kind of cellular memory (Web of stories). From the 
results, Hayflick concluded that cellular aging is based on the amount of times a cell 
doubles (Hayflick). 
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To test whether or not there were cell-signaling factors involved in this cessation 
of duplication, as opposed to internal factors, Hayflick paired adult cells and fetal cells 
together in culture. The results did not vary from previous data. The younger cells were 
unaffected by any factor involved in the older cells and continued to divide an average of 
about fifty times (Hayflick). Hayflick also found that change in a cell’s duplication 
potential was not caused by freezing the cell samples in liquid nitrogen because the 
unfrozen samples obtained similar results. Researchers who used WI-38 strains in their 
experiments also replicated the results of Hayflick’s experiment and found that the cells 
stopped dividing at about fifty replications. 
Hayflick’s conclusion drawn from his experimental results presented 
counterargument against Carrel’s theory that cellular replication is infinite. The data 
supported the idea that there is a cellular theory of aging, refuting Carrel’s hypothesis 
based on experiments with chick heart tissue in 1912 (Carrel). Before Hayflick’s 
discovery, scientists attributed the failure in infinite replication of human cells to 
incorrect laboratory practices or interference of a virus or other microorganism (web of 
stories). 
As a cause for cellular aging, Hayflick hypothesized that it can be a result of one 
or many targets of cellular damage (Hayflick). In particular, he claimed that this damage 
is likely associated with chromosomes. He called that damage hits, or errors in DNA 
replication that accumulate over time, which cause a more rapid onset of phase III in a 
cell and results in cellular aging. The hits on the DNA were associated with telomeres in 
the 1970s.  
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Hayflick’s work generated considerable interest due to his extensive data as well 
as the data from other researchers who replicated his experiments (Web of Stories). 
Cellular aging, however, was not confirmed until its association with telomeres in DNA 
replication in the late 1970s, when Alexey Olovnikov published his work on telomeres 
(Olovnikov). Elizabeth Blackburn, Carol Greider, and Jack Szostak later received the 
Nobel Prize in Physiology or Medicine in 2009 for their work telomeres, or repetitive 
sequences of DNA on the ends of chromosomes, and telomerase, the enzyme responsible 
for repairing telomeres. The scientists related telomeres and telomerase to cellular aging, 
as inspired by the Hayflick Limit.  
Hayflick’s experiment, published in “The Limited In Vitro Lifetime of Human 
Diploid Cell Strains,” contributed to the idea that cells undergo an aging process that is 
influenced by telomeres. The Hayflick Limit is applicable to adult cells as well as cells 
found in human embryos. Nature claims that Hayflick’s experiment is one of the most 
cited articles in all of biology (Wadman). As of 2013, the WI-38 fetal cell cultures 
established in Hayflick’s experiment are still used by scientists in biological research. 
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CHAPTER 3 
TELOMERES/TELOMERASE AND SENESCENCE 
Once scientists began to understand the different ways that cells experience death, 
or that some cells have a limited lifespan, there were questions as to what kept cells alive. 
In the 1970s and 1980s, Elizabeth Blackburn, Jack Szostak, and Carol Greider validated 
Hayflick’s hypothesis that cells contained intrinsic factors of aging. The scientist Alexey 
Olovnikov also hypothesized about intrinsic factors in aging, though Blackburn, Szostak 
and Greider were more recognized for their research in the nematode, Caenorhabditis 
elegans. They found that telomeres, or protective sequences of DNA on the end of 
chromosomes, shorten each time the cell replicates its DNA.  
Telomeres provide protection to cellular DNA by preventing DNA tangling, and 
some DNA mutations. Over time, telomeres reach what researchers call a critical length, 
where a cell is unable to replicate the DNA anymore, and the cell cannot repair serious 
damage to the DNA.  Blackburn and others hypothesized that telomeres affect cellular 
aging, and in 1989, Vicki Lundblad and Szostak validated the scientists’ hypotheses with 
research on yeast (Lundblad, Nobel). The critical length of telomeres also was found to 
correspond directly with the Hayflick limit.  
Blackburn, Szostak and Greider’s collaborations eventually led to the discovery 
and isolation of the enzyme that repairs telomeres, called telomerase. Telomerase repairs 
the ends of the chromosome, the telomere, during DNA replication as the cell prepares 
for division. The importance of telomerase is evident in an examination of immortalized 
cell lines such as hESCs.   
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HESCs and other immortalized cell lines such as HeLa cells are able to renew 
themselves and replicate in part because they produce the enzyme telomerase. As long as 
there is enough active telomerase within a cell, the cell appears to avoid the effects of the 
Hayflick Limit. In non-immortal cells such as those studied by Hayflick, the telomeres of 
chromosomes decrease little by little with each cellular division because they do not 
produce telomerase.  
After the discoveries of telomeres and telomerase, researchers had a method of 
quantifying senescence. With time, scientists found telomerase expression in many 
human cells. In 1992, it was found that human sperm cell telomere lengths do not 
decrease with age. Some studies demonstrated that telomere length was a heritable 
characteristic passed from parent to offspring, as was the case for sperm telomere length. 
The following Embryo Project articles give extended information on telomere and 
telomerase research. It is appropriate to start by examining the contributions of Carol 
Greider, who is one of the leading scientists involved in telomere and telomerase 
research.  
Carol Widney Greider (1961-) 
Bartlett, Zane, "Carol Widney Greider (1961-)". Embryo Project Encyclopedia (2015-01-26). ISSN: 1940-
5030 http://embryo.asu.edu/handle/10776/8283. 
Carol Widney Greider studied telomeres and telomerase in the US at the turn of 
the twenty-first century. She worked primarily at the University of California, Berkeley 
in Berkeley, California. She received the Nobel Prize in Physiology or Medicine in 2009, 
along with Elizabeth Blackburn and Jack Szostak, for their research on telomeres and 
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telomerase. Telomeres are repetitive sequences of DNA at the ends of chromosomes that 
protect chromosomes from tangling, and they provide some protection from mutations. 
Greider also studied telomerase, an enzyme that repairs telomeres. Without telomeres, 
chromosomes are subject to mutations that can lead to cell death, and without telomerase, 
cells might not reproduce fast enough during embryonic development. Greider's research 
on telomeres helped scientists explain how chromosomes function within cells. 
Carol Greider was born 15 April 1961 in San Diego, California, to Jean Foley 
Greider and Kenneth Greider. Greider also had a brother named Mark, one year older 
than she. Greider's parents both received their PhDs from the University of California, 
Berkeley, her mother in botany, and her father in physics. During the early 1960s, the 
Greider family moved often as Greider's parents accepted different academic teaching 
positions. In 1965, the family moved to Davis, California. In 1967, when Greider was in 
first grade, her mother died. Greider later reported that her mother's death played a role in 
learning how to take responsibility to do things on her own. In her statement for the 
Nobel Prize, Greider also notes that the death of her mother contributed to difficulties 
Greider had in school, especially after learning she had dyslexia. 
In 1971, Greider's father took a sabbatical from his position at the University of 
California, Davis, and moved to Heidelberg, Germany, with the family. As Greider states 
in her Nobel Prize biography, the foreign environment enabled her to make new friends 
and to recognize and enjoy differences between people. In 1972, the family left Germany 
and returned to Davis, where Greider attended junior high schools. Greider reported 
discovering an aptitude for biology in her junior year of high school. In 1979, she started 
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an undergraduate program to study marine ecology at the University of California, Santa 
Barbara in Santa Barbara, California. 
In 1982, Greider participated in a study abroad program at the University of 
GÖttingen, in GÖttingen, Germany, where she worked at the Max Planck Institute for 
Biophysical Chemistry. During her second semester, Greider attended a course on 
chromosomes taught by Ulrich Grossbach. Greider later said that she was entranced by 
the work being done on chromosomes in Chironomus flies. She finished her work on 
microtubules and switched to chromosomal work with Grossbac and others. Greider 
returned to Santa Barbara for her senior year, and she received her undergraduate degree 
in Biology in 1983. 
Greider then applied to graduate schools, and the University of California, 
Berkeley accepted her as a graduate student in molecular biology. Greider met Elizabeth 
Blackburn, a faculty member in the Department of Molecular Biology. After hearing 
about Blackburn's work on telomeres Greider planned to work with Blackburn. 
As a first-year graduate student, Greider worked in different labs and did not 
immediately work with Blackburn. She first worked with Richard Calendar, who studied 
the interactions between bacteriophages, or viruses that infect bacteria, to learn more 
about the properties of DNA. Next, Greider worked with Blackburn. Greider cloned 
telomeres to try to determine why those chromosomal ends did not shorten when the cell 
replicated. Her work was based on research conducted by Blackburn and Jack Szostak, 
who in 1982 were the first to identify telomeres in Tetrahymena, a ciliated single-celled 
protozoan. For that research, Szostak worked at Harvard Medical School in Boston, 
Massachusetts. In 1984, Greider joined Blackburn's lab to work on a telomere elongation 
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project. Greider began work on making extracts of the enzymes from Tetrahymena, the 
same organism that Blackburn and Szostak had used to identify telomeres. Greider made 
extracts of the enzymes from the cells in Tetrahymenato identify the enzyme responsible 
for telomere elongation. 
At the end of December 1984, Greider and Blackburn identified telomere terminal 
transferase as the enzyme that replicated telomeres in Tetrahymena, and in 1985 they 
published their results. Shortly after publishing their article, Greider and Blackburn 
shortened the name of the enzyme to telomerase, after Greider received feedback from a 
fellow student that the name was too long. In 1987, Greider and Blackburn began 
studying how genes produce the telomerase enzyme. After conducting experiments, 
Greider and Blackburn found that telomerase contains an RNA component, which is a 
template that enables telomerase to repair telomeres on chromosomes. Repaired 
telomeres enable organisms to replicate cells without potentially harmful mutations or 
without apoptosis. Greider and Blackburn published their results in 1987, the same year 
that Greider received her PhD in molecular biology. 
In 1987, Greider was hired as an independent researcher at Cold Spring Harbor 
Laboratory (CSHL) in Cold Spring Harbor, New York by CSHL president Bruce 
Stillman. Greider studied the sequence of nucleotides that comprise telomerase RNA, and 
she cloned and isolated the RNA sequence of telomerase. She published her results in 
1989. Then the CSHL hired her as a faculty member. She continued to research telomeres 
and telomerase activity in cells and their roles in the cell cycle through the late 1980s and 
early 1990s. 
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While at CSHL, Greider met Nathaniel C. Comfort, a historian of biology, who 
was working in the public affairs office at CSHL. The two married in 1993. In 1996, 
when Greider was pregnant with their son she suggested that CSHL should have a 
childcare facility. Officials of the laboratory agreed to her request, and Greider 
participated in the ground breaking of the facility while pregnant. Once her son Charles 
was born, Greider enrolled him in the childcare facility, and she often brought him to 
meetings and to her office. She also encouraged other women with children at CSHL to 
do the same. 
In 1997, Greider was offered a faculty position at Johns Hopkins University in 
Baltimore, Maryland. Her husband was concurrently offered a faculty position in George 
Washington University, in Washington, D.C. Greider and Comfort accepted their 
positions and the family moved to Baltimore, Maryland. At Johns Hopkins, while 
working with mice and yeast, Greider studied how cells function without telomerase. 
Greider and Comfort's second child was born in Baltimore in 1999. According to Greider, 
her job as a mother came before her work in the laboratory and the flexible work 
environment of her lab helped ensure that priority. In 2003, she became director of 
molecular biology and genetics, where she continued to work as of 2014. 
Greider received numerous awards, including the Albert Lasker Award for Basic 
Medical Research in 2006, and the Nobel Prize in Physiology or Medicine, which she 
received in 2009 along with Blackburn and Szostak. Greider received the awards in 
recognition for her accomplishments in telomere and telomerase research. She and 
Comfort divorced around the same time she received the Nobel Prize. 
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As of 2014, Greider was the youngest woman to receive the Nobel Prize in Physiology or 
Medicine, at the age of forty-eight. Some also recognize Greider as a leading woman 
scientist at a time when there were relatively few. Into the first decades of the twenty-first 
century, Greider researched telomeres in relation to cellular death, regenerative disease, 
DNA stability, and the relationship between stem cells and telomerase. 
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Elizabeth Blackburn, Carol Greider and Jack Szostak's Telomere and Telomerase 
Experiments (1982-1989)  
Bartlett, Zane, "Elizabeth Blackburn, Carol Greider and Jack Szostak's Telomere and Telomerase 
Experiments (1982-1989)". Embryo Project Encyclopedia (2015-03-24). ISSN: 1940-5030 
http://embryo.asu.edu/handle/10776/8308. 
Experiments conducted by Elizabeth Blackburn, Carol Greider, and Jack Szostak 
from 1982 to 1989 provided theories of how the ends of chromosomes, called telomeres, 
and the enzyme that repairs telomeres, called telomerase, worked. The experiments took 
place at the Sidney Farber Cancer Institute and at Harvard Medical School in Boston, 
Massachusetts, and at the University of California in Berkeley, California. For their 
research on telomeres and telomerase, Blackburn, Greider, and Szostak received 
the Nobel Prize in Physiology or Medicine in 2009. Telomeres and telomerase affect the 
lifespan of mammalian cells and ensure that cells rapidly develop within developing 
embryos. 
The scientists involved in the experiments with telomeres and telomerase came 
from a variety of disciplines. Blackburn worked at the University of California in 
Berkeley (UC Berkeley) from 1982 to 1989. In 1975, she had received her PhD in 
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molecular and cellular biology from the University of Cambridge in Cambridge, England, 
after which she did postdoctoral work with Joseph Gall at Yale University in New Haven, 
Connecticut from 1975 to 1977. 
As Blackburn's graduate student, Greider studied telomeres and telomerase at UC 
Berkeley from 1984 to 1987. Greider received her PhD in molecular biology in 1987 
from UC Berkeley and continued her research with Blackburn through 1989. Szostak had 
received his PhD in biochemistry from Cornell University in Ithaca, New York, in 1977, 
where he specialized in cloning yeast and in manipulating genes. Szostak began to study 
telomeres and telomerase after hearing a conference presentation given by Blackburn in 
1980, during which she explained her work on telomeres in Tetrahymena, a single-celled 
freshwater organism. After meeting Blackburn and discussing her work, Szostak accepted 
a position at Harvard Medical School in 1982, where he and Blackburn collaborated to 
investigate the functions of the telomeres of Tetrahymena in yeast. 
Blackburn and Szostak's 1982 experiment addressed an issue with how DNA 
replicates copies of itself within a cell. The issue was that after replication, one of the two 
DNA strands remains incomplete. When a cell replicates itself, the end of a strand of 
chromosomal DNA, the telomere, shortens. The telomere shortens because the enzyme 
that replicates DNA, DNA polymerase, only works in one direction on DNA. This 
process creates what scientists call a leading and a lagging strand during DNA 
duplication. The leading strand is named such because DNA polymerase moves in one 
direction across the nucleotide sequence, and replicates the DNA without any breaks in 
the genetic material. The lagging strand is composed of individual fragments of DNA 
formed by DNA polymerase (Okazaki fragments) that are later sealed together by the 
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enzyme DNA ligase to create one continuous strand. This strand is called the lagging 
strand because it can take longer to seal together the individual DNA fragments than the 
leading strand takes to continuously replicate a strand. The DNA polymerase detaches at 
the end of the lagging strand and leaves a space that measures a few nucleotides in 
length. The identity of those nucleotides remained unknown until Szostak and Blackburn 
published their results in 1982. 
To identify the nucleotides, Szostak and Blackburn removed what Blackburn 
hypothesized were the telomeres in Tetrahymena. The hypothesized telomeres were 
highly repetitive nucleotide segments of DNA at the ends of chromosomes. The 
researchers placed the telomeres in circular genetic material, called linearized plasmids, 
from yeast species. Blackburn and Szostak used yeast and Tetrahymena because of their 
distant evolutionary relationship from each other, and to see if the telomeres were similar 
across different species of eukaryotes. They found that the yeast added new DNA to 
the Tetrahymena telomeres, which led the researchers to conclude that telomeres were 
highly conserved evolutionarily, or similar across distantly related species, across yeast 
and Tetrahymena, and hypothetically across other species. Additionally, Blackburn and 
Szostak observed that the telomeres functioned similarly to each other in yeast 
and Tetrahymena. Blackburn and Szostak cut out pieces of the similar telomeres from 
each species and identified them by describing their sequences of nucleotides (DNA 
sequencing). The experiment confirmed the description of the telomere as a highly 
repetitive nucleotide segment, particularly rich in the nucleotide guanine, which 
accumulates at one end of chromosomal DNA. 
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In 1985, Greider and Blackburn further investigated the mechanism by which 
DNA was added to the ends of telomeres. Blackburn and Greider noted the composition 
of telomere ends, but they could not explain what was adding the guanine-rich ends to the 
DNA. In different species, the lengths of telomeres differ, and with the sequencing 
techniques available in the 1980s, scientists couldn't determine how DNA was added to 
the ends of telomeres. Telomeres also appeared to grow over time in Tetrahymena and 
yeast. Blackburn and Szostak hypothesized that a specific, not yet identified, enzyme 
added new DNA to the ends of telomeres. 
In 1984 when Greider joined Blackburn's lab, they formulated a procedure to 
discover that unidentified enzyme. They took extracts of Tetrahymena chromosomes, cut 
them into small pieces and added radioactively labeled nucleotides to help identify parts 
of the original DNA sequence. They observed which nucleotides were added to the 
sequence and also examined the changes in length. The radiolabeled nucleotides, which 
Greider prepared, indicated that there was an enzyme responsible for telomere additions. 
Greider and Blackburn labeled this enzyme as telomere terminal transferase, a name later 
shortened to telomerase. In 1985, Greider and Blackburn published the results of their 
experiment. The evidence that telomerase existed signified that cells contain a 
mechanism to repair the gap resulting from the lagging strand of DNA and polymerase 
detachment. Telomerase enabled cells to replicate themselves rapidly and without 
hindrance in developing organisms. 
Greider and Blackburn continued to investigate the structure and function of 
telomerase by studying the origin of the guanine-rich repeat sequences of DNA. Greider 
hypothesized that RNA provided the necessary template for guanine-rich repeat 
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sequences to be added to telomeres. Greider added RNase, an enzyme that breaks down 
RNA, and DNase, an enzyme that breaks down DNA, to the telomere extracts. She found 
that the RNase stopped the telomeres from getting longer. She and Blackburn published 
the results in 1987. Their results concluded that telomerase had an RNA component and 
could serve as a template for the process of DNA replication. 
After further experimentation from 1987 to 1989, Greider sequenced the RNA 
component of telomerase. Greider created multiple RNA probes that could bind to the 
partial RNA fragments that she had obtained from the 1987 experiment. Greider 
diagrammed what she hypothesized was the mechanism by which telomerase added 
nucleotides to telomeres. She published her experiment and model on the RNA 
component of telomerase in 1989, with Blackburn as a coauthor. 
Along with the work of Blackburn, Greider, and Szostak, others have showed that 
mammals have telomeres. In 1978, Blackburn had hypothesized that telomeres 
affect cellular aging, in relation to the Hayflick Limit, or the cell's limited capacity to 
divide from forty to sixty times before it can no longer replicate. Scientists such as 
Geraldine Aubert and Peter M. Langsdorp at the University of British Columbia in 
Vancouver, British Columbia validated Blackburn's original hypothesis. In 2009, 
Blackburn, Greider, and Szostak received the Nobel Prize in Physiology or Medicine for 
their research on telomeres and telomerase. The results of their work have influenced 
research related to cellular aging. 
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Telomerase in Human Development 
Bartlett, Zane, "Telomerase in Human Development". Embryo Project Encyclopedia (2015-03-23). ISSN: 
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Telomerase is an enzyme that regulates the lengths of telomeres in the cells of 
many organisms, and in humans it begins to function in the early stages of embryonic 
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development. Telomeres are repetitive sequences of DNA on the ends of chromosomes 
that protect chromosomes from sticking to each other or tangling. In 1989, Gregg Morin 
found that telomerase was present in human cells. In 1996, Woodring Wright and his 
team examined human embryonic cells and found that telomerase was active in them. 
Scientists manipulate telomerase in cells to give cells the capacity to replicate infinitely. 
Telomerase is also necessary for stem cells to replicate themselves and to develop into 
more specialized cells in embryos and fetuses. 
Carol Greider and Elizabeth Blackburn discovered telomeres in 1978. Greider 
was Blackburn's student at the University of California in Berkeley, California. 
Blackburn had used the protozoon Tetrahymena thermophila to study telomeres in the 
process of cellular replication. In 1985 Greider and Blackburn discovered 
in Tetrahymena terminal transferase, which later was called telomerase. Greider and 
Blackburn found that telomerase was a type of enzyme that organizes DNA at the end of 
the strand in a reverse fashion from normal transcription. Scientists label any enzyme that 
follows the reverse pattern as a reverse transcriptase. Telomerase consists of protein and 
RNA that add thymine and guanine (TTGGGG) repeated nucleotide sequences on the 
ends of chromosomes. Telomerase fills a gap on the chromosome that exists due to 
imperfect DNA replication. DNA replication is imperfect because there is a space where 
the enzyme DNA polymerase detaches from the DNA strand. 
In 1994 at the Cold Spring Harbor Laboratory in Cold Spring Harbor, New York, 
Lin Mantell and Greider showed that telomerase was necessary in germline and 
embryonic cells of developing frogs Xenopus laevis. For their work with telomeres and 
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telomerase, Greider and Blackburn received the Nobel Prize in Physiology or 
Medicine in 2009, along with Jack Szostak. 
Building upon the finding of telomerase in Tetrahymena, Gregg Morin studied if 
telomerase was present in human cells. In 1989, while working at Yale University in New 
Haven, Connecticut, Morin isolated telomerase from human HeLa cells. HeLa cells are 
named after Henrietta Lacks, a cervical cancer patient from whom the cells were taken. 
HeLa cells are cancerous cells that proliferate indefinitely. The telomerase that Morin 
found in the HeLa cells differed from the telomerase found in Tetrahymena. HeLa cells' 
telomerase had a six-nucleotide sequence of thymine, adenine and guanine (TTAGGG). 
Morin hypothesized that totipotent cells, or cells capable of becoming any types of cells 
such as embryonic stem cells, produced telomerase to retain the infinite replicative 
properties needed for an organism to develop. 
Mantell and Greider verified Morin's hypothesis in Xenopus in 1994. Mantell and 
Greider found that during early development, telomerase is highly active. Telomeres 
were active throughout embryogenesis and oogenesis in Xenopus egg cells. The 
researchers also found that germline cells, such as cells found in the ovaries 
and testes of Xenopus, continued to produce telomerase. Mantell and Greider further 
suggested that telomerase functions in germline cells to preserve telomeres for future 
generations. 
In 1996, scientists verified Morin's hypothesis in humans. Woodring Wright, 
Piatyszek Mieczyslaw, William Rainey, William Byrd, and Jerry Shay at the University 
of Texas Southwestern Medical Center in Dallas, Texas, performed an experiment that 
detected high amounts of telomerase activity in human blastocysts, and in tissues at 
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sixteen to twenty weeks after fertilization. The activity rapidly declined and became 
undetectable after the neonatal period, or the first twenty-eight days of a child's life post-
birth. Wright and his team concluded that the human body regulates and represses 
telomerase activity after birth except in some tissues. Particularly, Wright's team found 
that telomerase was expressed in fetal, newborn, and adult testes and ovaries, but not in 
mature sperm or eggs, which differed from the results found in Xenopus. Wright and his 
team hypothesized that the difference was due to the fact that human sperm telomeres do 
not shorten with age, and human zygotes produce telomerase after the first cell division, 
therefore egg cells need not carry telomerase. 
In 2001, researchers including Diane L. Wright at the Eastern Virginia Medical 
School in Norfolk, Virginia, found that telomerase is necessary for cells in human 
embryos to rapidly proliferate. Cells need telomerase during embryogenesis because as 
they replicate, their telomeres shorten. Without the presence of telomerase, the first few 
cells in the zygote would be unable to replicate and develop into an embryo and 
eventually a fetus. The scientists reported that telomerase was active in every stage of 
development of the embryo. They also observed that while telomerase activity was 
necessary for an embryo to develop, the amount of telomerase present did not predict the 
potential for embryonic growth. 
Scientists found that genetic variation between humans influences telomerase 
activity during development and adult life. In 2010, researchers including Gil Atzmon at 
the Albert Einstein College of Medicine in Bronx, New York, published a study that 
explains the effects of telomerase in centenarians of Ashkenazi Jewish descent. That 
research showed that the centenarians and their offspring showed increased production of 
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telomerase. Due to that increase, those studied had fewer than normal age-related 
diseases such as cardiovascular disease and diabetes mellitus, as well as other diseases 
caused by genetic mutations. The researchers named the genes associated with the 
increase in telomerase activity hTERT and hTERC. They further hypothesized that 
hTERT and hTERC became active during development and that their repression was not 
as drastic after birth for those studied as it was for those in a more general population. 
Although scientists researched the link between telomerase activity and the 
process of how cells replicate, some criticized the way the data was produced. Critics of 
the research, such as Harry Rubin at the University of California, Berkeley, California, 
argued that the data collected on telomerase could be skewed by experimental techniques. 
Rubin argues that incorrect data of telomerase activity can result from tumor cells within 
the population or the result of a virus that causes overproduction of telomerase. Others 
argued that scientists over emphasized research into telomerase and telomeres and that 
other elements of development and the cell cycle are overlooked due to the attention 
given to telomeres. 
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Telomeres are bits of DNA on the ends of chromosomes that protect 
chromosomes from sticking to each other or tangling, which could cause DNA to 
abnormally function. As cells replicate, telomeres shorten at the end of chromosomes, 
and this process correlates to senescence or cellular aging. Integral to this process is 
telomerase, which is an enzyme that repairs telomeres and is present in various cells in 
the human body, especially during human growth and development. Telomeres and 
telomerase are required for normal animal development because they protect DNA as it 
duplicates copies of itself. 
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In 1965, Leonard Hayflick's research at the Wistar Institute in Philadelphia, 
Pennsylvania, showed the limit to which cells duplicate themselves before aging. 
Hayflick established what became called the Hayflick limit, which states that a cell can 
divide forty to sixty times before it cannot divide further and begins to age. In the 1970s, 
scientists researched telomeres. Elizabeth Blackburn studied telomeres while she worked 
at Yale University in New Haven, Connecticut. Alexey Olovnikov in Russia related 
telomeres to cellular aging and to the Hayflick Limit. Although Blackburn had helped 
discover telomeres in 1975, two years before, in 1973, Olovnikov had hypothesized the 
existence of telomerase, the length of telomeres, and their connections to cellular aging in 
his study on the Hayflick Limit. Unaware of Olovnikov's research, Blackburn and Joseph 
G. Gall independently found a repetitive sequence of DNA at the end of chromosomes of 
the yeast, Tetrahymena thermophila. Blackburn and Gall published the results of their 
research in 1978. In 1982 Blackburn, then at the University of California in Berkeley, 
California, collaborated with Jack W. Szostak at the Harvard Medical School in Boston, 
Massachusetts. The pair isolated and cloned telomeres in Tetrahymena DNA. Blackburn, 
with the help of her student Carol Greider, then identified telomerase in 1984 and isolated 
it from Tetrahymena in 1989 Blackburn, Jack Szostak, and Carol Greider received 
the Nobel Prize in Physiology or Medicine in 2009 for their work to identify and isolate 
telomeres and telomerase. 
Blackburn and others found that cells age when the length of the telomeres in the 
cells shortens. Each time a cell replicates itself, the end of a strand of DNA or 
the telomere shrinks in length. The telomeres shrink across replications because the 
enzyme that replicates DNA, DNA polymerase, only works in one specific direction on 
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the DNA strand. It creates what is called a leading and a lagging strand of duplication. 
The leading strand receives its name because DNA polymerase constantly moves in one 
direction and replicates the DNA until it completes the strand of DNA without any 
breaks. The lagging strand is composed of individual fragments of DNA created by DNA 
polymerase, called Okazaki fragments, which are later sealed together by the enzyme 
DNA ligase to create one continuous strand. The name lagging strand derives from the 
fact that it lags behind the leading strand since lagging or leading strand can take longer 
to seal together the individual DNA fragments. The DNA polymerase detaches from 
DNA at the end of a lagging strand and leaves a space that measures a few nucleotides in 
length. Telomerase normally fills in the gap at the end of the DNA after the polymerase 
detaches from it. 
Telomerase, the enzyme that repairs telomeres, exists in high quantities in 
developing organisms and in embryonic stem cells. Some cells have higher amounts of 
telomerase activity than do others. As a human develops and cells replicate with greater 
frequency, excess telomerase is used and is later replenished only in minute quantities. At 
the end of the process of DNA replication, without telomerase to fill in the gaps of a new 
DNA strand, telomeres shorten with each cellular division. According to Blackburn, the 
Hayflick Limit is a result of decreased telomere length. Decreased telomere length also 
leads to chromosomal abnormalities that result in mutations in the genetic code, 
mutations that can cause cancer and further aging in humans. However, too much 
telomerase can also lead to cancer by helping cells to become functionally immortal by 
avoiding the Hayflick Limit. Immortal cells can carry mutations in unrepaired areas of 
the DNA, and they pass the cancerous mutations to other cells through replication. 
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Scientists continued researching telomerase, telomere activity, and cellular 
aging after Blackburn's experiments in the 1980s. Scientists studied how environmental 
factors could affect the length of telomeres and, consequently, cellular aging. In 2008, 
Geraldine Aubert and Peter Langsdorp at the Terry Fox Laboratory in Vancouver, 
Canada, published research showing that cells replicate in response to mutations in the 
genetic code or in response to stress. Aubert and Langsdorp showed that a cell will 
replicate to attempt to repair damaged DNA and, in turn, will shorten the telomeres. 
In 2012, Blackburn, Jue Lin, and Elissa Epel at the University of California in San 
Francisco, California, showed the influence of lifestyle on the length of telomeres 
and cellular aging in humans. They found that stress, nutrition, and personality influence 
the length of telomeres and telomerase enzyme activity. They defined stress as adverse 
life events such as death in the family or chronically sick children, and they found that 
personality also influences how a person perceives stressful events. The authors noted 
that those who perceived events as less stressful than what the researchers expected had 
longer telomere lengths compared to individuals who perceived events as more stressful 
than what researchers expected. Behaviors such as smoking or eating processed meats 
also correlated with shorter than normal telomere lengths. Also, those who took vitamin 
C or E supplements had longer than normal telomere lengths. The results of Blackburn 
and her team's experiment verified that environmental factors affect the length of 
telomeres. 
Some people have criticized telomere research. Harry Rubin, at the University of 
California in Berkeley argued that researchers who studied telomeres in relation to cancer 
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sometimes produce suspect data. Others argued that scientists pay too much attention 
on telomere research when they should also study other factors involved in the cell cycle. 
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Paternal Sperm Telomere Elongation and its Impact on Offspring Fitness 
Bartlett, Zane and Yang, Joanna. “Paternal Sperm Telomere Elongation and its Impact on Offspring 
Fitness”. (Citation pending publication in the Embryo Project Encyclopedia) 
Telomeres are the protective caps at the end of DNA strands that preserve 
chromosomal integrity and contribute to DNA length and stability. Because telomeres 
shorten with each cell division due to incomplete replication, the enzyme telomerase is 
present in certain cell lines that undergo repetitive divisions to replenish any lost length 
and to prevent degradation. Cells, and therefore organisms, with short telomeres are more 
susceptible to mutations and genetic disease. Research by Elizabeth Blackburn, Carol 
Greider, and Jack Szostak in the 1980s laid the foundation for telomere research in a wide 
array of fields, ranging from senescence, or aging, to cancer studies and prenatal 
development. That research earned them the 2009 Nobel Prize in Physiology or 
Medicine. In 1992, scientists found that telomere length (TL) in sperm increases with age 
as opposed to most other cells, where telomeres actually shorten. Strong TL correlations 
between father and child passed on in sperm imply that there are paternally heritable 
biological traits that can affect offspring’s fitness.  The offspring’s fitness can affect the 
longevity and health of future generations that continue to carry the heritable trait 
originally passed by the father.  
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 Since the research of telomeres and telomerase in the 1980s by Blackburn and her 
team, scientists have used embryonic and prenatal experimentation to provide insight on 
how telomeres preserve chromosomal integrity. Telomeres shorten with each cell 
replication due to DNA’s method of synthesis, which requires short strands of nucleic 
acids called RNA primers. Enzymes lengthen the RNA primers to form Okazaki 
fragments, or short strands of DNA, which enzymes combine to become one continuous 
strand. The RNA primers, however, occupy a space on the DNA template and once 
removed, there is a remaining gap at the end of the DNA.  This phenomenon, known as 
the end-replication problem, creates loss of genetic material that cells counteract by 
producing telomerase to repair telomere ends. 
Scientists link TL’s heritability, demonstrated initially through studies on twins, 
and its implications for predicting longevity and genetic stability, to telomerases’ key role 
in counteracting the end-replication problem of DNA. Researchers demonstrate that 
Leukocyte, or white blood cell telomere length (LTL) in particular is heritable, although 
mechanisms behind the extreme diversity of LTL length in humans are unknown as of 
2014. While researchers in the late twentieth and early twenty-first centuries studied 
maternal influence on developing oocytes extensively, paternal effects of sperm were less 
understood. Scientists attribute the lack of understanding to the idea that there is a 
stronger perceived maternal influence on children. For example, scientists found that 
mRNA, or protein, comes from the egg, and not from the sperm. Some scientists 
challenge the idea that maternal factors alone influence children with research that shows 
how oocyte viability is dependent on both mother and father. 
 In 1992, Allsopp and his research team found that sperm telomeres do not 
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decrease with age like their somatic (body) cell counterparts. That research indicated that 
a mechanism, through telomerase or some other method, is in place to protect germ-line 
cells. With longer TL associated with more potential cell divisions, researchers became 
interested in studying sperm interactions with eggs. Scientists state that TL can be 
influenced by heredity, age, and gender, but significant variability in telomere length 
across the human population indicates that some other, more potent, determinant at hand. 
A 2005 study by Brad Unryn and colleagues at the University of Calgary, in Calgary, 
Canada, further demonstrated that there is a positive correlation between TL and 
increased paternal age. They hypothesized that this may account for the large range of TL 
observed throughout the human population, especially if paternal contribution to TL is 
cumulative over generations. 
 As a genetic mechanism, the specifics behind sperm TL elongation remain elusive 
as of 2014, even if its implications in development are well established. Scientific 
understanding of how sperm TL contributes to offspring TL, however, has changed 
drastically. In 2007, Tim De Meyer and his colleagues in Ghent, Belgium, further 
corroborated the results of Unryn and his team through analysis of 2433 volunteers, about 
half of whom were male and the other half were female. De Meyer and his team 
compared information on the volunteers’ telomere lengths to statistical information of 
their parents’ ages at conception and the current ages of the volunteers. De Meyer 
showed that older fathers’ ages at conception were positively associated with longer TL 
in their children. The study provided a quantitative gain of seventeen additional base 
pairs in TL for each additional year of age in the father. Furthermore, differences between 
daughters and sons were insignificant, contradicting earlier thoughts on gender-specific 
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variability. The results added evidence to substantiate the sperm’s role in contributing to 
TL variance and added to a growing body of work demonstrating how TL is not 
completely reset during embryonic development in the zygote, but rather can be inherited 
from father to child.  
De Meyer and his colleagues’ work was verified through further studies by 
Masayuki Kimura and his team by demonstrating how a father’s age positively correlates 
with his children’s leukocyte telomere lengths (LTL). Kimura’s study was conducted in 
four distinct populations and they found that children’s LTL increased anywhere from 
half-fold to twofold with each additional year of their fathers’ age. Sperm telomere 
elongation in older men and its potential effect on offspring LTL holds implications for 
potentially increased longevity and lessened age-related disorders in offspring of older 
fathers.  
In 2010, a study by Katarina Nordfjäll and her colleagues at Umeå University in 
Umeå, Sweden, further demonstrated that a child’s TL correlated more with his or her 
father’s TL than with his or her mother’s TL. There was no statistical difference between 
father-to-son or father-to-daughter, and there was even an observed correlation between 
grandfather and grandchild. That association over the course of multiple generations 
lends credence to the idea that sperm TL contributes to population-wide TL variability 
due to paternal inheritance. Tracing TL over multiple generations down the paternal 
family line suggests a concentration upon the father’s lineage when looking to examine 
potential TL in children. The 962 individuals examined in Nordfjäll’s study also 
demonstrated diminishing father-child correlations over time, which shows that 
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environmental (non-genetic) factors such as oxidative stress can influence telomere 
length fluctuations throughout a lifetime.  
While the correlation between a father’s sperm TL and his child’s TL is largely 
accepted by scientists as of 2014, the implications of a longer TL for biological fitness of 
the child are not so clear. Longer TL, when viewed in itself, is a positive trait in most 
cells. However, aging can negatively affect genomic stability when mutation 
accumulations and other lifestyle factors counteract the positive benefits of having longer 
telomeres. A 2009 study by Silvia García-Palomares and colleagues in mice found that 
older paternal ages at conception have negative effects on offspring viability. The 
scientists individually housed male mice at a variety of different ages with same-aged 
female mice. They monitored the resulting offspring for two generations (F1 and F2).  F1 
females from older fathers had longer intervals between births indicating reduced 
fertility, and F2 generation mice had lower weaning weights overall. F1 mice also 
displayed shorter lifespans accompanied by a lower incidence of tumor development due 
to early death, and decreased body weight at death.  
A 2010 literature review by Gideon Sartorius and Eberhard Nieschlag at the 
University of Domagkstrasse, in Muenster, Germany, concluded that older paternal age at 
conception negatively influences offspring fitness overall. While TL increases in a subset 
of sperm cells and longer telomeres may prevent early disintegration of DNA, it may also 
prevent natural mechanisms of apoptosis, or cell death, from occurring in unhealthy 
sperm because a longer TL can reduce incidences of cellular disease. Beyond telomere 
interactions, increased age in males correlates with decreased sexual activity, infertility, 
increasing miscarriage rates, and deflated male hormones, such as testosterone, in the 
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body. Sartorius and Nieschlag state that if paternal TL’s effect on offspring TL does 
contribute somehow to offspring fitness, researchers must consider other factors to 
provide a comprehensive understanding of how age at conception has a positive or 
negative impact. According to the authors of the study, isolating the specifics of whatever 
positives there are may also prove to increase longevity for future generations and 
provide a better quality of life in a society that is gradually having children at an older 
age. 
 While the mechanisms behind sperm telomere elongation remained elusive in the 
beginning of the twenty-first century, scientists have established its heritability. 
Researchers claim that whether or not older paternal age at conception contributes to 
increased offspring fitness overall is debatable. The potential for the longer telomeres of 
paternal sperm to transfer their properties of longer telomere length in offspring may 
contribute to a better understanding of just how telomeres contribute to embryonic 
development and subsequent longevity. 
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CHAPTER 4  
SHEEP, SENESCENCE, AND STEM CELLS – CLONING AND SCNT TO "TURN 
BACK THE CLOCK" 
Scientists heavily studied telomeres and telomerase through the late 20th century 
in hopes of finding a way to activate or deactivate immortality in cell populations. 
However, some scientists were looking for a way to acquire immortalized cell lines 
through a different method: cloning. Cloning, as defined by the NIH, “describes the 
processes used to create an exact genetic replica of another cell, tissue or organism. The 
copied material, which has the same genetic makeup as the original, is referred to as a 
clone” (MedlinePlus).  
In 1952, Robert King and Thomas Briggs conducted experiments that involved 
transplantation of cell nuclei. They designed a protocol to remove the nucleus from an 
unfertilized frog egg, which they then replaced with the nucleus of a cell from a different 
frog blastocyst. Briggs and King observed that the resulting frog embryo developed 
normally. Their work was quickly recognized in the scientific community, and scientists 
were eager to try a similar technique in other animal species.  
From the 1950s onward, scientists used transplantation techniques similar to 
Briggs and King’s technique to produce a variety of clones. However, mammalian 
embryos proved difficult to clone. Though it was possible to transfer the nucleus of a 
mammalian cell into a vacant egg cell, resulting embryos failed to develop past the 
morula. Many hypothesized that the fault lies in the methods for transferring nuclei, as 
the transfer required researchers to puncture the cell membrane of the egg cell, thus 
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resulting in cellular damage. In 1984, Steen Willadsen modified Briggs and King’s 
methods and successfully cloned a sheep embryo. Though Willadsen’s additions allowed 
cloned mammalian embryos to divide past the morula stage, the cloned embryos never 
grew into adult organisms.  
 Perhaps one of the most famous examples of cloning occurred in 1997, when 
scientists at the Roslin institute in Edinburgh, Scotland, successfully cloned a sheep, 
which they named Dolly. Dolly was the first mammal cloned from an adult somatic cell. 
Previous experiments in mammalian cloning relied on using cells from the blastocyst, 
rather than fully differentiated adult cells. The new technique became known as Somatic 
Cell Nuclear Transfer (SCNT). 
With the modifications that the Roslin Institute Scientists made in cloning 
techniques, it had become possible to take adults cells and revert them into embryonic 
cells capable of becoming a complete organism. Fueled in part by the publicity of Dolly 
the sheep, scientists eagerly sought ways to apply the same SCNT techniques to human 
cells. To understand the historical context of SCNT, it seems appropriate to examine 
Embryo Project Encyclopedia articles related to Dolly the Sheep, beginning with the 
history of Keith Campbell, one of the key researchers who contributed to SCNT research.  
Keith Henry Stockman Campbell (1954-2012) 
Bartlett, Zane, "Keith Henry Stockman Campbell (1954-2012)". Embryo Project Encyclopedia (2014-06-
27). ISSN: 1940-5030 http://embryo.asu.edu/handle/10776/8013.  
 
Keith Henry Stockman Campbell studied embryo growth and 
cell differentiation during the twentieth and twenty-first centuries in the UK. In 1995, 
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Campbell and his scientific team used cells grown and differentiated in a laboratory to 
clone sheep for the first time. They named these two sheep Megan and Morag. Campbell 
and his team also cloned a sheep from adult cells in 1996, which they named Dolly. Dolly 
was the first mammal cloned from specialized adult (somatic) cells with the technique of 
somatic cell nuclear transfer (SCNT). Campbell helped develop cloning techniques that 
used a common form of connective tissue cells (fibroblasts). Besides working at the 
Roslin Institute, in Edinburgh, Scotland, for most of his career, Campbell also taught at 
the University of Nottingham in Nottingham, England. 
Campbell was born 23 May 1954 in Birmingham, England, to Marjorie Regina 
Smith Campbell and Henry Stockman Campbell. Campbell had one younger sibling, a 
sister. At age three, Campbell and his family moved to Perth, Scotland, where Campbell 
began his formal education. His mother noted that he was a curious and adventurous boy 
who loved the outdoors and she often had to sweep frogs out of the family kitchen after 
Campbell had brought them home. Campbell returned to Birmingham with his family 
when he was eight, and he remained in Birmingham until he was twenty-one. Campbell 
attended school at the King Edward VI Grammar School for boys on a scholarship, but he 
received no outstanding grades. 
Campbell said he did not like the atmosphere of that school, so he took a 
vocational exam and that qualified him as a medical laboratory technician at the age of 
nineteen, in 1973. Campbell worked at the Selly Oak Hospital in Birmingham, England. 
Campbell later said that the work as a technician did not intellectually satisfy him 
because he could not perform his own research. He enrolled at Queen Elizabeth College 
in London, England, to study microbiology. He quit his job at the hospital the same day 
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he received his national certificate in medical technology. The certificate qualified 
Campbell as a medical technologist, but he later said that he did not want to continue 
with this career. 
At Queen Elizabeth College Campbell studied the mechanisms of life cycles for 
cells. He graduated in 1978 with a Bachelor of Science in microbiology. After receiving 
his degree, Campbell worked as a medical technologist in southern Yemen until he 
returned to England a year later. He was in England from 1979 to 1980 as part of a 
program that aimed to eradicate a fungus that attacks trees, Dutch elm disease, from parts 
of southern England. Campbell said that he was also unsatisfied with this work. 
Campbell began his PhD in 1980 at the Marie Curie Institute in Oxted, England. 
He joined a group led by Nutan Bishun that studied chromosome structures in cells. 
Bishun left due to illness shortly after Campbell joined, which left Campbell without a 
supervisor. Campbell worked alone on his PhD for six months until 1983 when the Marie 
Curie Institute awarded him a scholarship to study and finish his PhD at the University of 
Sussex in Sussex, England. There, Campbell studied the cell cycle with the direction of 
Chris Ford. Campbell learned of a technique to mature egg cells (oocyte) in vitro, a 
technique he later used at the Roslin Institute. 
At the University of Sussex, Campbell studied the embryos and oocytes of South 
African clawed frogs (Xenopus laevis). He read the works of John Gurdon, at 
the University of Oxford in Oxford, UK. Gurdon researched cloning and nuclear 
transplantation, a technique of transplanting the nucleus of one cell to a host egg cell that 
had had its nucleus removed. Campbell met another biologist who studied nuclear 
transplantation, Karl Illmensee from the University of Geneva in Geneva, Switzerland, 
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who further fueled Campbell's interest in cloning and the cell cycle. During his time at 
Sussex, Campbell worked in the lab with Chris Hutchinson and collaborated with Ron 
Laskey and Julian Blow at Cambridge University in Cambridge, England. In 1986, 
Campbell received a PhD for his dissertation titled "Aspects of Cell Cycle Control in 
Yeast and Xenopus." 
After receiving his PhD, Campbell returned to Scotland. Campbell said he 
enjoyed mountain biking, hiking, and the outdoors, and he felt that Scotland was where 
he could enjoy these activities and have a career of his choice. He became a postdoctoral 
research fellow in the zoology department at Edinburgh University in Edinburgh, 
Scotland. Campbell joined a group led by Peter Fantes. The group worked to control the 
cell cycle of Schizosaccharomyces pombe, a species of yeast that reproduces by fission. 
At Edinburgh, Campbell met Murdoch Mitchison, who worked in cellular biology and 
developed the fission yeast S. pombe as a model system for studying the cell cycle. 
In 1989, Campbell left his fellowship in Edinburgh and began another post-
doctoral fellowship at the University of Dundee in Dundee, Scotland, where he worked 
again with Hutchinson on frog embryonic development. In his studies of frog embryos, 
Campbell studied cell nuclei, and he began to hypothesize about the ability to reprogram 
an already determined cell. In 1991, Campbell saw a job posting for a post-doctoral 
position at the Roslin Institute. Later he said that he saw the opportunity as a better way 
to provide for his romantic partner, Angela, and for their first daughter Clair, and to 
pursue cloning. Campbell applied for and received the job offer. Campbell and Angela 
later had another daughter named Lauren. 
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At the Roslin Institute, Campbell met and became friends with Ian Wilmut, who 
led a research group that would eventually clone Dolly. Campbell studied the effects 
of cloning by transferring the nucleus of one cell to another (nuclear transplantation). 
According to Wilmut, Campbell felt that the key to cloning was to transplant 
the nucleus to the egg during the second stage of meiosis. Campbell also altered the 
amounts of Maturation Promoting Factor, or MPF, a protein activity modifier (kinase) 
that regulates the cell cycle in many animal cells. Campbell and Wilmut first 
experimented on cattle embryos for this research. 
Using the techniques developed with the cattle embryo experiments, Campbell 
and Wilmut tried cloning sheep because they were cheaper than cattle and because the 
Roslin Institute already had grown sheep cells in the laboratory. Campbell first tried to 
clone sheep stem cells, but he was unsuccessful because sheep stem cells were difficult to 
grow in the laboratory. 
Two years later, in 1995, Campbell successfully cloned two Welsh Mountain 
lambs using nuclei from sheep embryo cells grown in the laboratory. Campbell started 
with a multicelled sheep embryo. He used techniques of mechanical and enzymatic 
digestion to disassociate the cells apart, and he suspended the individual cells in a liquid. 
He then placed the cells into cell culture medium and incubated them at thirty-seven 
degrees centigrade. Those cells were called the primary culture. After several days 
Campbell removed a portion of the cells from the primary culture and placed them into 
fresh cell culture media, a process called the first passage. Campbell repeatedly passed 
cells to new cultures from six to thirteen times, and he used the nuclei from the 
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transferred embryo cells, instead of nuclei from stem cells or primary culture embryo 
cells, to clone the two lambs. 
The researchers transplanted nuclei from the transferred cells into oocytes, each of 
which had had its original nucleus removed, to form embryos, and then they implanted 
those embryos into surrogate ewes. When the time was near for the lambs to be born, 
Campbell, and other members of the team took turns watching the ewes from midnight to 
five in the morning each day to ensure that the pregnant ewes had no complications. The 
names of the lambs born in 1996 were Megan and Morag and they were the first 
cloned sheep. Campbell successfully transplanted nuclei from differentiated embryonic 
cells because he had discovered how to place these cells into a state called quiescence, 
which is a state when cell activity is limited. Quiescence more commonly called G0. This 
resting state is normally unattainable in stem cells, but is attainable in differentiated 
embryonic cells. Wilmut attributed the success of the experiment to Campbell's 
hypothesis that if you removed nuclei from differentiated embryonic cells at the G0 stage 
and transplanted them to oocytes with high MPF, then you could clone differentiated 
embryonic cells. With the success of Megan and Morag, Campbell insisted that 
researchers could clone sheep with nuclei from fully differentiated adult cells as well as 
from differentiated embryonic cells. This claim conflicted with the long-standing theory 
that once embryonic cells differentiated into specific kinds of adult cells, those adult cells 
could not return to a totipotent state, or retain the ability to reinitiate the development of a 
complete organism. 
Campbell continued his research with the techniques developed from the Megan 
and Morag experiment and funding from a new partnership with PPL Therapeutics in 
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Roslin, Scotland. Campbell and his team extracted adult mammary cells from a six-year-
old sheep and performed nuclear transplantation from these adult mammary cells into 
oocytes that had had their original nuclei removed. The team then implanted two hundred 
seventy-seven embryos, each of which had a nucleus and DNA from an adult mammary 
cell, into surrogate ewes. One of these attempts resulted in a pregnancy and successful 
birth of a female sheep in 1997. They named the sheep Dolly, after the singer Dolly 
Parton. They chose the name because Dolly was cloned from a mammary gland cell and, 
according to Wilmut, Parton offered an excellent example. Dolly the sheep's existence 
helped correct theories about the impossibility of cloning new organisms with 
differentiated adult cells. Wilmut later said that Campbell was the main contributor to the 
Dolly project. In a retrospective article, Wilmut claimed that Campbell deserves two 
thirds of the credit for cloning Dolly. 
After Dolly was born, many people discussed the implications for 
human cloning as well as the authenticity of the experiment. However, genetic tests 
proved Dolly to be a clone, and accusations of fraud faded. Campbell defended his 
experiments, but opposed human cloning. At the same time as the Dolly experiment, 
Campbell cloned two more sheep named Taffy and Tweed from a nuclei of fetal 
fibroblast cells. By using fetal fibroblasts, Campbell then helped genetically modify and 
create a cloned sheep named Polly. Campbell left the Roslin Institute in 1997 during the 
Polly experiment to become the head of the embryology department for PPL 
Therapeutics, and he finished the Polly experiment with PPL Therapeutics. 
Polly was the first mammal that scientists made to have genes from another 
species (transgenic) through genetic engineering techniques. Researchers altered 
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Polly's genes to express Factor IX, which is a human protein that doctors use to treat a 
type of hemophilia, a blood clotting disorder. Campbell's team incorporated the human 
Factor IX gene by transfection into embryonic fibroblast cells of sheep. Next they 
transplanted the fibroblast nuclei into unfertilized sheep oocytes to produce embryos, 
which they implanted in ewes, one of which yielded Polly. Campbell continued to work 
with and clone livestock, including sheep, pigs, and cattle. In 1999, Campbell helped 
clone the first gene-targeted mammal. These mammals were sheep named Cupid and 
Diana. Gene targeting is the process of placing genes on the chromosome exactly where 
they will be best expressed and controlled. Campbell's experiments with Cupid and Diana 
in 1999 led to the first piglets cloned from somatic cells, which were born in the year 
2000. Campbell planned to use gene-targeted cloned pigs to transplant tissues from one 
species of animal to another. 
In 1999, Campbell left PPL Therapeutics and became a professor of animal 
development at the University of Nottingham in Nottingham, England, where he 
continued his work on cloning. He also tried to make stem cells out of already 
differentiated cells. According to Wilmut, Campbell did not like bureaucracy and he 
enjoyed his time as a professor because he was better able to pursue his own research. 
During his time at Nottingham, Campbell served on scientific advisory boards for various 
academic organizations and companies. In 2008, Keith Campbell, Ian Wilmut, 
and Shinya Yamanaka in Japan received the Shaw Prize for Medicine and Life Sciences. 
Campbell died on 5 October 2012 at the age of fifty-eight. 
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Bartlett, Zane, ""Sheep Cloned by Nuclear Transfer from a Cultured Cell Line" (1996), by Keith Campbell, 
Jim McWhir, William Ritchie, and Ian Wilmut". Embryo Project Encyclopedia (2014-09-19). ISSN: 1940-
5030 http://embryo.asu.edu/handle/10776/8203.  
In 1995 and 1996, researchers at the Roslin Institute in Edinburgh, Scotland, 
cloned mammals for the first time. Keith Campbell, Jim McWhir, William Ritchie, 
and Ian Wilmut cloned two sheep, Megan and Morag, using sheep embryo cells. The 
experiments indicated how to reprogram nuclei from differentiated cells to produce live 
offspring, and that a single population of differentiated cells could produce multiple 
offspring. They reported their results in the article "Sheep Cloned by Nuclear Transfer 
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from a Cultured Cell Line" in March 1996. This experiment led the Roslin team to later 
clone mammals from adult body cells and to genetically engineer mammals. 
Campbell developed techniques to reprogram cell nuclei. Campbell had used 
techniques of nuclear transplantation from earlier work with frog embryos at the 
University of Sussex in Sussex, UK. McWhir worked primarily with embryonic stem 
cells in livestock at the University of Cambridge in Cambridge, UK, before working at 
the Roslin Institute. At the Roslin Institute, Ritchie worked with large and small 
animal embryology and specialized in the ability to work with small tools and specimens 
under a microscope, called micromanipulation. Wilmut studied cow embryos and 
researched possible implications for cloning them. 
The foundation for the 1995 through 1996 cloning experiment came from 
experiments performed on cow embryos in 1993 by Campbell, Wilmut, and Ritchie. In 
the cow experiments, Campbell, Wilmut, and Ritchie removed an egg cell's 
(oocyte) nucleus and replaced it with the nucleus of another cell. They identified a 
protein that regulates the cell cycle of an activity modifier called maturation promoting 
factor (MPF). MPF influences how a recipient oocyte accepts a donor nucleus. A low 
concentration of MPF in the oocyte means that the oocyte can receive a nucleus without 
chromosomal damage, called a universal recipient. Oocytes with a high MPF 
concentration can be used only if the nucleus has two viable copies of each chromosome 
or if the nucleus is placed while the cell is in a resting state called quiescence. 
The scientists tested two hypotheses in the sheep experiments from 1994 to 1995. 
The first hypothesis was Jim McWhir's, who said that to have embryos created from 
nuclear transfer, it was necessary to have nuclei that could produce cells that could 
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develop into any cell type, called totipotent cells. McWhir hypothesized that researchers 
could culture totipotent sheep cells. The second hypothesis, presented by Campbell, was 
the claim that reprogramed differentiated cells could be totipotent. Campbell suggested 
that to use nuclei from differentiated cells for cloning, scientists only had to ensure that 
the cytoplasm from the receiving egg cell and the donor nucleus were in quiescence. 
The scientists selected four groups of female sheep (ewes). Using two distinct 
breeds of sheep ensured that the offspring produced were the result of cloning and not the 
result of eggs fertilized within the oviduct. Scottish Blackface sheep provided the 
oocytes, which had nuclei removed (enucleated) and which became the receiving 
enucleated oocytes. These sheep constituted the first of the four groups used. The 
scientists obtained the oocytes by injecting ewes with a follicle-stimulating hormone, 
called gonadotropin-releasing hormone, which facilitates the release of oocytes from the 
ewes' ovarian follicles. The scientists flushed out the oocytes from the ewes' fallopian 
tubes with a saline solution then collected the oocytes. 
Ritchie removed the nucleus from each oocyte under a microscope by extracting 
the nucleus with a glass pipet. Scientists confirmed enucleation by placing donor oocytes 
in calcium-free media containing a chemical that fragments DNA, Cytochalasin B, and a 
fluorescent dye that specifically stains DNA, Hoechst 33342, and looked at the glass 
pipet under ultraviolet light. If the pipet glowed due to the fluorescent dyes present in the 
DNA, and if the cytoplast, or inner part of the cell, did not glow, then enucleation was 
successful. In 1994, the cytoplasts used were all low in MPF protein, thus ensuring the 
cytoplasts could accept nuclei. In 1995, the scientists divided the cytoplasts into three 
different MPF protein groups. Cytoplasts in the first group had low amounts of MPF 
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protein, the second group had high amounts of MPF protein at first, but declined to low 
MPF after embryo fusion, thus emulating natural fertilization, and the third group had 
high amounts of MPF protein both pre- and post-embryo fusion. 
The scientists used two processes to obtain nuclei (karyoplasts) to implant into the 
enucleated oocytes. The first used McWhir's theory of deriving totipotent cells from nine-
day-old embryos, which had formed into an embryo disc. The researchers placed these 
cells in a medium that contained nutrients as well as a protein that discourages 
cell differentiation but not cell multiplication, the protein leukemia inhibition factor 
(LIF). The researchers placed the embryo disc in an incubator for a few days then 
removed the cells from the medium and divided them into four new cultures. This 
process is called a passage, meaning the cells were passed into a new medium. McWhir 
and his colleagues continued for thirteen passages. By the fourth passage, the cells began 
to differentiate, despite the presence of LIF proteins in the medium. The scientists named 
the cells that maintained totipotency after thirteen passages totipotent for nuclear transfer, 
or TNT4. Accordingly, they called this portion of the experiment the TNT4 section. 
Next, the scientists tested Campbell's hypothesis called the cell-cycle step of the 
procedure. Campbell's hypothesis was that they could reprogram diploid cells nuclei that 
were in a state of quiescence by placing them into a cytoplast with high concentrations of 
MPF protein. Campbell said that cells deprived of growth factors entered quiescence. 
Welsh Mountain sheep provided the karyoplasts for the testing of Campbell's hypothesis. 
The experimenters held cytoplasts in place with a glass pipet. Using another glass pipet, 
Ritchie inserted the karyoplasts into cytoplasts through the hole created from enucleated 
cytoplasts. The researchers then placed combinations of cytoplasts and karyoplasts 
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between two electrodes and fused them together. To do so, they used electrical fusion 
methods developed by Steen Willadsen at the British Agricultural Research Council's 
Institute of Animal Physiology at Cambridge, UK, in the 1980s. A gelatinous solution 
obtained through boiling algae (agar) coated over the fused embryos protected them from 
environmental factors between transfers. 
The scientists injected a third group of ewes 
with gonadotropin releasing hormone to simulate pregnancy. They surgically implanted 
the altered embryos into the ewes. These sheep were temporary holders of the embryos. 
The ewes incubated the embryos in their oviducts until the embryos began to differentiate 
and contain an inner cell mass, called blastocysts. The scientists then removed the 
blastocysts and examined them under a microscope to ensure development had begun. 
The scientist's implanted two blastocysts, one into each uterine horn, of 
the surrogate Scottish Blackface ewes of the fourth group. Those ewes gave birth after 
about one hundred and forty-seven days. The researchers monitored the ewes to ensure 
there were no complications. Of the forty-seven embryos from TNT4 blastocysts, six 
were born. Two resulted from a sixteen-cell blastocyst, one resulted from a first 
passage blastocyst, one from a second passage blastocyst, and two from a third passage 
blastocyst. There was one pregnancy established from a sixth passage blastocyst, but it 
was lost at about seventy to eighty days. McWhir said that the lack of births from higher 
passage embryos was due to other factors, such as infections. The claim was disproved in 
the cell-cycle portion of the experiment. 
In the cell-cycle portion, the researchers found no significant difference between 
variations in concentrations of MPF proteins among the blastocysts whose karyoplasts 
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were in the quiescent state. There were thirty-four embryos from the cell-cycle 
experiment, which developed from passages six to thirteen karyoplasts and transferred 
into ewes. The thirty-four embryos produced eight fetuses and resulted in five live births, 
all exhibiting characteristics of the same female Welsh Mountain lamb. Two of the lambs 
died within a few minutes of birth and a third one died ten days after birth due to 
unknown factors. The remaining two lambs, named Megan and Morag, were healthy and 
normal after nine months and could reproduce normally. Morag became pregnant by 
a ram when she was eighteen months old and had a lamb of her own. Of the two, Megan 
lived to at least age ten in 2005. 
The results of the second half of the experiment enabled the scientists to show that 
the quiescent phase is the period of time when chromatin, or a mix of DNA and protein, 
undergoes differentiation and modification resulting in successful blastocysts past the 
sixth passage. The quiescent phase enables researchers a greater window of time to work 
with DNA. The window enabled the Roslin team to genetically engineer the sheep Polly, 
as reported in the 1997 article "Human Factor IX Transgenic Sheep Produced by Transfer 
of Nuclei from Transfected Fetal Fibroblasts." The 1995 and 1996 experiments also 
opened the possibility of cloning a sheep from an already differentiated adult somatic 
cell, which led to the creation of Dolly the Sheep in 1997. 
"Sheep Cloned by Nuclear Transfer from a Cultured Cell Line" is a precursor to 
many other scientific experiments involving cloning. Campbell and his colleagues 
showed that differentiated cell's DNA had the ability to become totipotent. Totipotent 
cells could create many offspring from cell line, thus producing identical offspring. In the 
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early twenty-first century, embryology and cloning methods use the techniques and 
theories developed from these experiments. 
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In the 1990s, Ian Wilmut, Jim McWhir, and Keith Campbell performed 
experiments while working at the Roslin Institute in Roslin, Scotland. Wilmut, McWhir, 
and Campbell collaborated with Angelica Schnieke and Alex J. Kind at PPL Therapeutics 
in Roslin, a company researching cloning and genetic manipulation for livestock. Their 
experiments resulted in several sheep being born in July 1996, one of which was 
a sheep named Dolly born 5 July 1996. Dolly was the first sheep cloned and developed 
from the nuclei of fully differentiated adult cells, rather than from the nuclei of early 
embryonic cells. They published their results in "Viable Offspring Derived from Fetal 
and Adult Mammalian Cells" (abbreviated Viable Offspring) on 27 February 1997. 
In 1993, Wilmut, Campbell, and collaborators experimented on cow embryos at 
the Roslin Institute. These experiments helped develop the theory that differentiated cells 
in an appropriate environment could develop similar to embryonic cells. For the process 
of cloning organisms without defects, the cow embryo experiments revealed the optimal 
cell cycle stage and the need to avoid chromosomal damage when transferring nuclei. 
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Further information came from experiments described in the 1996 article titled 
"Sheep Cloned by Nuclear Transfer from a Cultured Cell Line." Campbell, McWhir, 
Ritchie, and Wilmut conducted experiments in which they cloned sheep from an 
established embryonic cell line experiments that produced the sheep named Megan and 
Morag. The scientists developed techniques and concepts from the sheep experiments, 
including how transferring nuclei during the resting state in the cell cycle called 
quiescence improves success rates. In the experiments, the scientist removed 
the nucleus from an egg cell and inserted a donor egg nucleus to replace the 
removed nucleus, a modified version of the technique called somatic cell nuclear transfer. 
Wilmut was part of various animal embryo experiments at the Roslin Institute. 
Schnieke studied bioengineering at the Heinrich-Pette Institute in Hamburg, Germany, 
and subsequently at the Whitehead Institute of the Massachusetts Institute of 
Technology in Cambridge, Massachusetts. Before coming to the Roslin Institute, she 
researched modes to transmit genetic material into cells using RNA viruses of 
the Retroviridae family called retroviral vectors to incorporate therapeutic genes into host 
cells. She also worked on the production of cross-species genetic modified or transgenic 
animal models, and preventing specific gene expression in a process called gene 
knockout. 
McWhir worked with embryonic stem cells in livestock at the University of 
Cambridge in Cambridge, United Kingdom, before working at the Roslin Institute. Kind 
was Schnieke's husband and worked at PPL Therapeutics. Keith Campbell had previously 
studied the reprogramming of cell nuclei as well as the transplantation of frog nuclear 
material. Campbell used an experimental method developed by Robert Briggs and 
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Thomas Joseph King in 1952 called nuclear transplantation at the Institute for Cancer 
Research in Fox Chase, Pennsylvania, which in 1974 became the Fox Chase Cancer 
Center in Philadelphia, Pennsylvania. 
Alan Coleman directed research at the Roslin Institute at the time of the Dolly 
experiments. Coleman received his PhD in 1974 while studying with John 
Gurdon at Cambridge University, he worked on theories of cloning, and he often used 
frogs for his research. Gurdon's 1975 experiments did not show that adult cell nuclei 
could create fully developed adult frogs. However, after the sheep experiments in 1996 
showed the success of transplanting cells in quiescence, the scientists at the Roslin 
Institute hypothesized that they could clone a mammal from adult cells, despite Gurdon's 
results that indicated otherwise. Wilmut later said that Coleman was somewhat skeptical, 
due to his experience with Gurdon, of what the scientists could accomplish. 
The researchers tested their hypothesis with embryonic, fetal, and adult sheep cell 
samples. The embryonic cells came from a day-nine embryo, the fetal cells came from a 
day-twenty-six fetus, and the adult cells came from a mammary gland of a six-year-old 
female sheep (ewe) that was in her last trimester of pregnancy. Schnieke suggested using 
the mammary cells because they appeared similar to the embryo cells used to clone the 
first sheep Megan and Morag in the 1995 sheep experiment. The scientists used the 
method derived from 1995 experiments "Sheep Cloned by Nuclear Transfer from a 
Cultured Cell Line" to implant the cells of different ages into recipient egg cells. 
The cells began embryo formation and the scientists then transferred the embryos 
that developed into a thin-walled early embryo, called a blastocyst, into awaiting ewes, 
and they used ultrasound to check on prenatal development. The results of 
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the ultrasound showed twenty-one fetuses developing normally in fifty to sixty days into 
the experiment. After the fifty to sixty day interval, the scientists continued to perform 
ultrasounds in fourteen-day intervals. Sixty-two percent of the fetuses were lost during 
the intervals after the fifty to sixty days, which, they suggested in the experiment was 
much greater than the natural prenatal loss of six percent. 
The scientists dissected ewes whose fetuses did not survive to investigate why the 
fetuses did not develop. They found that four of the dead fetuses were specimens from 
embryo-derived cells. Two of these fetuses had abnormal liver development, but other 
than this defect, there was no sign of infection or other irregularity in development from 
the ewes or the fetuses. 
Eight ewes gave birth to live lambs and the offspring represented each of the three 
cell types, four lambs were born from embryo-derived cells, three were born from fetal 
cells, and one was born from adult mammary-derived cells. There was one lamb born 
from fetal cells that died a few minutes after birth. After conducting a post-mortem 
analysis, the researchers found no abnormalities or signs of infection in this lamb. The 
researchers concluded that of all of the lambs born, twelve and a half percent died soon 
after birth. They considered the loss as similar to the eight percent perinatal loss 
of sheep born naturally. Each of the lambs showed characteristics of the breed that 
donated the nuclei and not the characteristics of the breed that donated the cytoplasts. 
These characteristics indicated that the lambs born were clones of the cell that donated 
their nuclei and not from the originating egg (oocyte) donor. DNA analysis also indicated 
that each of the lambs' DNA came from their nuclear donors. 
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The researchers recommended further experimentation to determine exactly what 
stage in the cell cycle is optimum for deriving nuclear and oocyte donors. The results of 
their experiment point to using cells that are in the quiescent state, but the experiment 
itself did not use the optimum cell cycle stage to retrieve donors' oocytes. 
In the 1997 article, the scientists reflected on the sheep born from mammary cells, 
Dolly. According to the scientists, she was the first mammal to develop as a clone from 
an adult cell. They also said that there is a possibility that among the cell culture there 
could have been an undifferentiated stem cell present. An undifferentiated stem cell could 
have been responsible for allowing Dolly to develop to term. Regardless of this small 
probability, the birth of Dolly showed that once cells mature, control of gene expression 
is by the cell nucleus as well as changes in the cytoplasm. According to Campbell, this 
experiment helped to explain the reprogramming of cell DNA and consequently, the 
process of differentiation of stem cells into specific types of cells. 
After the results of the experiment were published, Dolly and the scientists 
responsible for cloning her received much publicity. Dolly had her photo taken by sixteen 
film crews and sixty photographers within the first few weeks of the announcement. 
Wilmut later said that Dolly, amidst all of the attention, only became more tame and 
spoiled than she was before. Reactions from the media were at first critical and negative. 
According to Campbell, the negative attitudes toward Dolly and cloning came largely 
from implications that the same techniques would enable scientists to clone humans. 
Wilmut later mentioned that Gurdon reported being shocked that Dolly existed 
because Gurdon could not produce similar results in his own experiments with frogs 
using adult nuclei. The Vatican and other religious groups voiced fears 
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about cloning humans. The President of the United States in 1997, Bill Clinton, called for 
a worldwide moratorium on similar experiments and asked a bioethics commission to 
report on the implications of the Dolly experiment and the ethical questions in relation to 
human cloning. Some scientists claimed that Dolly was not a clone of an adult cell at all, 
but that she developed from a stem cell present in the mammary tissue. Another paper 
published in 1998 that showed Dolly indeed developed from an adult differentiated cell 
and refuted these claims. 
The controversies behind the Dolly experiment diminished with time as other 
experiments verified the results of those at the Roslin Institute. Other scientists soon 
cloned other livestock, and scientists in Japan cloned offspring from a Japanese Black 
cattle bull named Kamitakafuku in 1998. The Dolly experiment also enabled a later 
experiment, "Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from 
Transfected Fetal Fibroblasts" in which researchers cloned sheep that had human genes. 
Dolly developed as normal sheep do. Dolly bred with a male sheep and gave birth 
to six lambs, the first born in 1998. In autumn of 2001, Dolly developed arthritis. The 
cause of the arthritis was unknown, but it was not attributed to her cloned status. In 2000, 
one of the cloned sheep in the experiment died of a pulmonary virus that causes incurable 
tumors in sheep. Dolly died of the same disease on 14 February 2003, likely due to 
exposure to this virus in 2000. 
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In the 1990s, researchers working at the Roslin Institute in Edinburgh, Scotland, 
performed cloning experiments in collaboration with PPL Therapeutics in Roslin, 
Scotland, on human coagulation factor IX, a protein. The team of scientists used the 
methods identified during the Dolly experiments to produce transgenic livestock capable 
of producing milk containing human blood clotting factor IX, which helps to treat a type 
of hemophilia. By using a cell's resting state, called quiescence, or G0, and transferring 
modified nuclear material from one cell to an egg cell that had had its nuclear material 
removed, the researchers developed a method to produce genetically modified mammals, 
including humans. Angelika E. Schnieke, Alexander J. Kind, William A. Ritchie, Karen 
Mycock, Angela R. Scott, Marjorie Ritchie, Ian Wilmut, Alan Colman, and Keith H. S. 
Campbell published the results of their experiments as "Human Factor IX Transgenic 
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Sheep Produced by Transfer of Nuclei from Transfected Fetal Fibroblasts" (hereafter 
called "Human Factor IX"). The article details the methods that produced the 
cloned sheep named Polly, as well as other cloned and genetically altered sheep. 
In 1985, Robert E. Hammer's group at University of Pennsylvania in Philadelphia, 
Pennsylvania, produced animals that expressed genes from other species, called 
transgenic animals. Scientists genetically manipulated the animals in a process called 
pronuclear microinjection. In this technique, scientists inject DNA containing the desired 
gene into the nucleus of the egg, called a pronucleus, just before the pronuclei of 
the egg and sperm combine during fertilization. Some of the resulting animals are born 
with the injected genes expressed, but the success rate is low. Genetic material can also 
recombine in such a way that it becomes a detriment to the organism, or in such a way 
that not all of the cells in the organism have the gene. 
In 1996 research on sheep embryos at the Roslin Institute, prior to the "Human 
Factor IX" experiment, established the claim that genetic alterations on adult body 
or somatic cell nuclei were possible. The researchers found that cloned sheep could 
express genes from another species by transferring altered nuclei into embryonic cells. 
The 1997 article "Viable Offspring Derived from Fetal and Adult Mammalian Cells" by 
Wilmut, Schnieke, and Jim Mcwhir, Kind, and Campbell reported the earlier sheep 
embryo experiments. 
Other information for "Human Factor IX" came from the 1996 experiment, 
"Sheep Cloned by Nuclear Transfer from a Cultured Cell Line." Campbell, McWhir, 
Ritchie, and Wilmut cloned sheep from embryonic cells grown in a laboratory in 1996. In 
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that experiment, the researchers established that if they transferred genetic material into a 
cell that was in quiescence, then they could more efficiently clone the cells. 
Before coming to the Roslin Institute, Schnieke studied the modes of transmission 
for RNA viruses, the production of cross-species genetic modification, or transgenic 
animal models, and the deactivation of specific genes from producing proteins. Kind was 
Schnieke's husband and worked at PPL Therapeutics. Ritchie specialized in 
micromanipulation procedures, or the ability to work with small tools and specimens 
under a microscope. He had previously performed procedures in other sheep embryo 
experiments, and he had helped with the same techniques that enabled the cloning of 
Dolly the sheep in 1996. Mycock was a technician who helped with embryological 
manipulation procedures in the lab with Ritchie. Scott was a technician working for PPL 
Therapeutics. Scott multiplied the cell cultures needed for the experiment. Marjorie 
Ritchie, William Ritchie's wife, organized the surgeries needed to implant 
the sheep embryos. Lastly, Wilmut researched animal genetics and was part of various 
animal embryo experiments at the Roslin Institute. Coleman was research director of the 
Roslin Institute at the time of the Dolly and Polly experiments. Campbell studied 
microbiology and had worked previously with reprogramming cell nuclei as well as 
transplantation of nuclear material in other experiments at the Roslin Institute. 
The team of scientists used the methods identified during the Dolly experiments 
to produce transgenic livestock capable of producing milk containing human blood 
clotting factor IX, which helps to treat a type of hemophilia. Scientists had produced 
transgenic livestock since 1985, but only about five percent of these animals expressed a 
transgenic DNA, or transgene, in their own genomes. Among these animals, few of the 
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transgenes passed naturally to offspring. The researchers claimed that it is simpler to 
incorporate foreign DNA into adult cell nuclei as opposed to juvenile nuclei, a process 
called transfection. The scientists, first transfected adult cells and then used the methods 
introduced from cloning Dolly to transfer the modified nuclei into awaiting enucleated 
oocytes, and then they cloned a transgenic sheep. 
The scientists used donor nuclei from cells, which the scientists said were fetal 
fibroblast cells, of thirty-five-day-old fetuses of a Poll-Dorset sheep. The donor nuclei, 
modified to be immune to the antibiotic neomycin, enabled the scientists to check that the 
cells in fetal sheep were from the implanted embryo. Immunity to neomycin would also 
identify the cells modified to have the transgenes. The researchers used a method called 
lipofection, which uses the chemical lipofectamine to penetrate the outer membrane of 
cells, to insert the DNA into these cells. Some fetal fibroblasts were non-transfected and 
used as controls. 
The scientists deprived the cells of growth factors and induced them into a state of 
quiescence. The scientists then found that even though the cells had been transfected, 
they could withstand the lack of growth factors and resumed the cell cycle without 
damage after the reintroduction of the growth factors. The researchers transplanted four 
types of nuclei into enucleated egg cells: male nuclei without transfection, female nuclei 
without transfection, female nuclei with transfection of the FIX gene at less than five 
copies, and female nuclei with the transfection of the FIX gene with more than ten 
copies. 
The researchers then transplanted the embryos into Scottish Blackface sheep, 
examined the pregnancies, and recorded the resulting births. Of the lambs born, there 
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were one non-transfected male, three non-transfected females, two transfected females 
with more than ten copies of the gene, and one transfected female with less than five 
copies of the gene. One of the female transfected lambs expressed the gene products at a 
particularly high level. The lamb was cloned from the Poll Dorset breed of lamb and was 
therefore name Polly. Each of the transgenic lambs was completely transgenic and not 
partially transgenic. A partially transgenic lamb would contain only a few cells that 
express the gene. Sheep born from microinjection techniques often are partially 
transgenic. Cloning produced one transgenic lamb per 20.8 sheep, as opposed to one 
transgenic lamb produced per 51.4 sheep by microinjection. The experiment indicated 
that cloning procedures produce a greater number of transgenic lambs than 
do microinjection techniques. 
The scientists found some of the births problematic. The gestations of all of the 
lambs were longer than the normal gestational term for this particular breed of sheep. 
There were no increases in mortality rate or disease, in the ewes however, a result that 
Wilmut indicated was important in understanding that genetic modification does not 
increase death rate. 
Outside the research team, scientists questioned whether transgenic animals were 
capable of reproducing and having offspring that contained the same genes. Eventually 
the transgenic sheep reproduced and had offspring with the same FIX protein present in 
the cells. 
According to Wilmut, animal activists advocated against and misunderstood this 
experiment. Some activists claimed that Polly contained human characteristics. Wilmut 
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explained that while Polly's genome contains a human gene, it is only one gene out of 
thousands of normal sheep genes. 
The "Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from 
Transfected Fetal Fibroblasts" experiment successfully produced a sheep that can express 
a human gene resulting in a human protein. Quiescence and nuclear transfer improved the 
ability to produce transgenic animals. 
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The Roslin Institute was established in 1993 in the village of Roslin, Scotland, as 
an independent research center by the Biotechnology and Biological Sciences Research 
Council (BBSRC), and as of 2014 is part of the University of Edinburgh in Edinburgh, 
Scotland. Researchers at the Roslin Institute cloned the Dolly the sheep in 1996. 
According to the Roslin Institute, Dolly was the first mammal to develop into an adult 
from the transfer of the nucleus of an adult sheep cell into an ovum with the 
nucleus removed. The Roslin Institute performs genetic and medical based animal studies 
to help investigate human physiology and medicine and to improve agricultural research. 
The Roslin Institute studies embryology, cloning, hormones, and genetic alterations in 
animals and techniques such as somatic cell nuclear transfer. 
Prior to the establishment and naming of the Roslin Institute in 1993, 
the University of Edinburgh created the Institute of Animal Genetics in 1919, the 
precursor to the Roslin Institute. In 1947 the Agricultural Research Council, later called 
the Agriculture and Food Research Council (AFRC), created the Poultry Research Centre 
(PRC) and the Animal Breeding Research Organisation (ABRO) as part of the Institute of 
Animal Genetics to help farmers find efficient ways to produce more food and livestock. 
The AFRC changed the name of the Institute of Animal Genetics to the Unit of Animal 
Genetics (UAG) and the University of Edinburgh maintained its presence at the UAG. In 
1985, the AFRC reviewed greater than thirty Institutes and Units, among them were the 
UAG, PRC, and ARBO. The review contributed to the closure of the UAG in the same 
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year and the combining of PRC and ABRO with the Institute of Animal Physiology, 
located at the Babraham Institute in Cambridge, United Kingdom. The name of the new 
institute was the Institute of Animal Physiology and Genetics Research. In 1985, the staff 
relocated from ABRO to the PRC site located in Roslin, Scotland, and they formed the 
Edinburgh Research Station of the Institute of Animal Physiology and Genetics Research. 
In 1992, the AFRC planned to separate the Roslin and Babraham Institutes. The 
AFRC provided each institute with unique objectives. The objective for the Roslin 
Institute was to focus on livestock improvements. On 1 April 1993, the officially named 
Roslin Institute formed as an independent institution owned by the BBSRC. In 1995, the 
Institute became a company limited by guarantee, which meant that it was a non-
profit organization. The Institute was sponsored by a Scottish Charity and funded by the 
BBSRC. In 2008, the Roslin Institute became part of the College of Medicine and 
Veterinary Medicine of the University of Edinburgh, and the old legal entity continued as 
the Roslin Foundation. In 2011, the main research center for the Roslin Institute moved 
from Roslin to a new building located in Easter Bush, Scotland, on the University of 
Edinburgh Veterinary campus. As of 2014, the Roslin Institute remained affiliated with 
the University of Edinburgh and received funds from the BBSRC and the Roslin 
Foundation. 
Various committees and groups run the Roslin Institute. All of the committees 
report to the Roslin Institute Executive Committee. The committees include the Science 
Management Group, which leads research and sets scientific goals, and the Business 
Finance Group, which handles everything else relating to business and finances of the 
institute. A director or chairperson leads the institute´s executive committee and the 
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director reports to the University of Edinburgh. The director of the Roslin Institute in 
2014 is David Hume. 
The Roslin Institute was founded on six principles with the collaboration of the 
BBSRC. The first principle was to enhance animal health and welfare through knowledge 
of genetic factors affecting resistance to disease. The second principle was to enhance 
sustainability and productivity of livestock systems and food supply chains through 
understanding of reproductive and developmental biology. The third principle was to 
enhance food safety by understanding interactions between disease-causing organisms 
and animals. The fourth principle was to enhance human health through an understanding 
of basic mechanisms of health and disease and comparative biology of animal species. 
The fifth was to identify new and emerging process of infectious disease transmission 
between species, called zoonoses, and to understand how pathogens might cross from 
animals to humans. The sixth principle was to enhance the quality of life for animals by 
studying the mechanisms and behaviors associated with optimizing their environment and 
life experiences. As of 2014, these goals organized the Roslin Institute. 
Researchers have pursued those goals through experiments at the Roslin Institute. 
These include experiments performed on cow embryos in 1993 by Ian Wilmut, William 
Ritchie, and Keith Campbell. These preliminary experiments led researchers to 
clone sheep from differentiated cells in the experiment entitled "Sheep Cloned by 
Nuclear Transfer from a Cultured Cell Line" by Campbell, Wilmut, Ritchie, and Jim 
McWhir in 1996. The scientists developed the techniques used in this sheep experiment 
that researchers applied to many future Roslin Institute experiments, including 
the cloning of Dolly the sheep. Campbell also formulated the plan to place cells in the 
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resting state, called quiescence, or induced cellular stasis, necessary for transfer 
and cloning of adult cells during the sheep experiments. According to Wilmut, placing 
cells in quiescence was an important insight needed to understand the mechanics 
of cloning and the cell cycle that are universal in mammals, including humans. 
Experiments conducted by the organization included the "Viable Offspring 
Derived from Fetal and Adult Mammalian Cells" experiments in 1996. These 
experiments cloned sheep from adult sheep body or somatic cells. The scientists named 
the cloned sheep Dolly. She was the first mammal cloned from an adult differentiated 
cell. Dolly became famous internationally and the Roslin Institute received much 
recognition from the scientific community. The director of the institute at the time of the 
experiment was Graham Bulfield. Among the scientists in the experiment were Wilmut, 
McWhir, and Campbell, who had also contributed to previous sheep and cow embryo 
experiments at the Roslin Institute. 
The work performed at the Roslin Institute spurred debates on the issue 
of cloning human beings. Some people argued against the practice of cloning animals 
because they said it would lead to cloning humans. Others claimed that cloning would 
bring great advances. Many of the scientists who worked at the Roslin Institute in 1996 
received phone calls requesting clones of deceased loved ones. 
After the Dolly experiment, the Roslin Institute continued to clone animals. The 
Institute aimed to engineer animals to produce proteins that could act as medicines in 
large quantities. The animals could produce cheaper, purer, and non-contaminated 
pharmaceuticals. In 1997, the Roslin Institute developed a sheep that produced a human 
protein in its milk in the experiment titled "Human Factor IX Transgenic Sheep Produced 
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by Transfer of Nuclei from Transfected Fetal Fibroblasts." The Roslin Institute worked to 
transfer human genes into animal cells (transgenic animals). For example, in 2000, Roslin 
researchers modified pigs to reduce the potential rejection rate of transplanted organs 
from other animal species (xenotransplanted) into humans. However, a few scientists 
argued that altering and researching human embryos as opposed to animals could make 
more progress. 
In the year 2001, the Roslin Institute contacted the licensing agency for clinics 
and research involving human embryos in the UK, the Human Fertilisation and 
Embryology Authority (HFEA), to receive a license to work with cloning human 
embryos. The license was delayed for a variety of reasons. According to Wilmut, these 
reasons involved heavy amounts of regulatory paperwork as well as meetings with many 
committees and ethical assessments involving the HFEA. Furthermore, controversies 
were also present over the request to the HFEA to work on human embryos. For example, 
anti-abortion parties criticized the Roslin Institute in 2002 for requesting permission to 
experiment on human embryos. In 2004, a research group led by Woo-Suk Hwang in 
Seoul, South Korea, reported to have cloned human embryos using somatic cell nuclear 
transfer. The Journal retracted the paper after learning that Hwang´s group falsified much 
of the data. The political reaction from the Hwang scandal further delayed the Roslin 
Institute´s HFEA license, which it received in February of 2005. The Institute studied 
motor neuron disease in humans and how early development can affect this disease, but 
the Institute used donated embryos as opposed to cloned embryos. By 2013, the Roslin 
Institute no longer cloned animals, Wilmut left in 2005 to become director of the Centre 
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for Regenerative Medicine at the University of Edinburgh and most of the group 
members had moved on to other organizations. 
Roslin researchers have further experimented with transgenic animals and genetic 
manipulation in animals. An example involves a type of chicken that the Institute calls a 
genetically modified chicken. Scientists have genetically altered these chickens so they 
do not transmit avian bird flu. Roslin researchers have also investigated animal behavior, 
for example, scientists at the Institute have investigated the role of 
the hormone vasopressin in animal behavior and mating. According to Wilmut, the 
Institute also frequently receives correspondence in regards to animal cruelty and testing. 
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Somatic Cell Nuclear Transfer in Mammals (1938-2013) 
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In the second half of the twentieth century, scientists learned how to clone some 
species of mammals. Scientists have applied somatic cell nuclear transfer to clone human 
and mammalian embryos as a means to produce stem cells for laboratory and medical 
use. Somatic cell nuclear transfer (SCNT) is a technology applied in cloning, stem cell 
research, and regenerative medicine. Somatic cells are cells that have gone through 
the differentiation process and are not germ cells. Somatic cells donate their nuclei, 
which scientists transplant into eggs after removing their nucleuses (enucleated eggs). 
Therefore, in SCNT, scientists replace the nucleus in an egg cell with the nucleus from 
a somatic cell. 
Although Karl Illmensee first cloned a mammal in 1981, other scientists had 
theorized and developed the techniques needed for SCNT in the form of nuclear 
transfer. Hans Spemann, who taught zoology at the University of Freiburg in Freiburg, 
Germany, theorized about SCNT in his 1938 book Embryonic Development and 
Induction. Spemann proposed to transplant a nucleus from an already differentiated cell 
from an embryo into an egg after removing the egg's nucleus. However, the technology 
required for this kind of experiment was not available to Spemann at that time, so he 
could not test his theory of nuclear transfer or SCNT. Robert King and Thomas Briggs 
developed the necessary protocol to conduct preliminary nuclear transfer at the Institute 
  101 
for Cancer Research and Lankenau Hospital Research Institute in Philadelphia, 
Pennsylvania, in 1952. The same nuclear transfer techniques serve as the basis for SCNT. 
While researching how embryos differentiate in 1952, Briggs and King 
transplanted the nucleus from an early embryonic blastula cell of a Rana 
pipiens frog embryo to an unfertilized egg after removing its nucleus. To enucleate the 
eggs, Briggs and King used a small glass needle to puncture the cell membrane, enter the 
cytoplasm, and suck out the nucleus of the egg cell. Briggs and King then transplanted 
the donor nucleus from a separate blastula cell to replace the nucleus that they removed 
from the egg cell. Briggs and King observed that the embryo developed normally. 
Researchers struggled to clone mammals using the same procedure that Briggs 
and King used on frogs. In 1975, Derek Bromhall in Oxford, UK, conducted experiments 
using rabbit embryos and showed that, after a certain stage in development called 
the morula stage, embryos produced from nuclear transfer died. Bromhall hypothesized 
that they died as the result of complications from the punctures made in the cell 
membrane during the transfer. 
Scientists performed nuclear transfer only on amphibians until 1981, when 
Illmensee in Geneva, Switzerland, claimed to have cloned mice using nuclear transfer 
technique. His work resulted in the birth of three live mice. Illmensee's experiments came 
under scrutiny and an investigation occurred concerning the veracity of his claims. 
Although the investigators never found conclusive evidence against Illmensee, the 
investigation cast doubts as to whether or not he had used nuclear transfer to clone the 
mice. 
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Scientists struggled to perform nuclear transfer on mammals larger than 
mice. Steen Willadsen at the Institute of Animal Physiology in Babraham Institute in 
Babraham, United Kingdom, was the first to clone a sheep embryo in 1984. Willadsen 
modified the technique of Briggs and King. After transferring the nucleus, Willadsen 
fused the embryo together using an electrofusion apparatus that has small electrodes that 
produce an electrical current. Willadsen coated the embryo with an agar jelly made from 
algae to reduce the damage caused by entry of the glass needle into the cell membrane. 
Once he had coated the embryos with agar jelly, Willadsen placed the embryos into the 
tied oviducts of a sheep, and he observed that the embryos were growing. From this 
experiment, Willadsen made viable mammalian embryos using his modified techniques, 
but they didn't grow into adult organisms. 
In 1996, Keith Campbell, Jim McWhir, William Ritchie, and Ian Wilmut at the 
Roslin Institute in Edinburgh, UK, used nuclear transfer techniques to clone a sheep that 
was born and grew into an adult. The team manipulated a stage in the cell cycle called 
quiescence, when the cell undergoes a period of supposed hibernation and ceases to 
develop. Campbell induced quiescence in the donor blastocyst nuclei before transferring 
them to recipient egg cells by depriving the cells of proteins called growth factors. The 
change in the state of the donor nuclei before entering the receiving egg cells enabled 
embryos to develop to term in surrogate ewes. 
According to Wilmut, the next experiment applied the same procedure to 
the nucleus of a fully differentiated adult cell as opposed to a blastocyst cell. The Roslin 
team hypothesized that the nuclear transfer procedure started by Briggs and King could 
be applied to somatic cells, thus becoming somatic cell nuclear transfer as opposed to just 
  103 
nuclear transfer. The Roslin Institute performed this step in 1997. The result of the 
experiment was Dolly the sheep. 
Dolly was the first mammal cloned from a fully differentiated adult cell. The main 
difference in the techniques producing Dolly was that the scientists used adult cell nuclei 
as opposed to the embryonic cell nuclei used in previous sheep experiments. After Dolly 
was born, the scientists applied these techniques in genetically modified mammalian 
embryos. Quiescence enabled the scientists to perform genetic modifications on 
the nucleus of the cell because growth factors were not altering the inserted DNA. In 
1997, a Roslin Institute team used similar techniques to genetically modify Polly 
the sheep to express a human protein. After the success of Dolly and Polly, some 
scientists worked to clone human embryos using SCNT, however there were social, 
ethical and legal controversies over the practice. Many disagreed with the claims that 
scientists could or should clone, or perhaps genetically modify, humans using SCNT. 
Scientists sought ways to clone human embryos without causing controversy. In 
2011, Scott Noggle and his team at the New York Stem Cell Foundation in New York, 
New York, used SCNT to retrieve human embryonic stem cells. Although, Noggle's team 
did not perform SCNT using the same methods that produced Dolly. In fact, Noggle and 
his colleagues aimed to avoid the social and ethical implications of working with human 
embryos. Instead of removing the nucleus of the receiving egg cell before transfer, the 
scientists kept the egg nucleus and inserted the donor nucleus into the egg cell. As a 
result, the embryo developed into the blastocyst stage where scientists could extract stem 
cells. The chromosome count, however, was sixty-nine as opposed to the normal forty-
six, because it contained the chromosomes from the full nucleus as well as 
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the egg nucleus, which only contains half, or twenty-three of the chromosomes in 
a zygote. This result meant that the blastocyst could not result in a pregnancy leading to 
birth because the cells would not progress to a further developmental state. 
Embryonic stem cells are derived from these blastocyst cells. 
Scientists report that SCNT is a plausible technique for creating 
human embryonic stem cells without extra chromosomes. In 2013, scientists in Oregon 
succeeded in using SCNT to reprogram somatic cells to become embryonic stem cells. 
After examining Noggle's research, Masahito Tachibana and his team at the Oregon 
National Primate Research Center in Hillsboro, Oregon, used the same methods that 
Campbell and his team had used to clone Dolly, but they also added a few extra 
procedures. The key differences were that they removed the spindle apparatus, which is a 
responsible for movement of chromosomes in cellular mitosis and meiosis, from the 
donor egg cell before removing the egg cell nucleus. They reinserted the spindle 
apparatus into the cell when they inserted the donor nucleus. After removing the spindle 
apparatus, they also added caffeine, which inhibits the enzyme protein phosphatase, 
which activates proteins that begin cellular replication in the cytoplasm. Because the 
spindle apparatus was removed and the cytoplasm inactivated, the scientists could 
perform their procedures without risk of premature activation of the cell resulting in 
cellular damage and death. The results of the experiment showed that the cells altered 
with SCNT reached the blastocyst stage and produced viable embryonic stem cell lines of 
normal chromosome count. As of 2014, doctors use this version of SCNT for medical 
therapies and treatment, described as therapeutic cloning. 
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Controversies due to SCNT largely arise from the possibility of cloning humans. 
In 2003, a private company called Clonaid headquartered in Las Vegas, Nevada, claimed 
to have cloned the first human baby, called Eve, using SCNT. However, Clonaid did not 
allow scientists to perform a DNA test on Eve to confirm that she was indeed a clone, and 
therefore many in the scientific community doubted their claims. As of 2014, 
controversies arose over the possibility of human clones from SCNT. Some criticized the 
scientists who used SCNT to clone human stem cells in Oregon. The Oregon scientists 
justified their research by claiming that their only goal was to produce embryonic stem 
cells and not to produce a fully developed human being. 
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CHAPTER 5 
STEM CELLS AND SENESCENCE - MODERN RESEARCH 
Moving into the late 20th and early 21st centuries, there is a growing body of 
research related to senescence and immortalized cell lines. With the successful 
application of SCNT, the scientists at the Roslin Institute introduced a method of 
acquiring human embryonic stem cells more readily. They also showed that the nucleus 
of a fully differentiated cell was capable of becoming a viable embryonic stem cell. 
However, SCNT is not a perfect technique. Though scientists attempt to mitigate the 
negative effects of the initial removal of the cell nucleus, it is difficult to eliminate all risk 
factors.  
In 2006, researchers in Kyoto, Japan, found an alternative method of acquiring 
pluripotent human stem cells. Rather than transplanting cell nuclei, this new method 
involved incorporation of viral DNA into a fully functional cell, thus bypassing the 
potential negative effects of nucleus removal. The viral DNA caused adult cells to 
become pluripotent stem cells. They called the cells induced pluripotent stem cells, or 
iPSCs. This novel technique provided a way for production of immortalized cell lines 
without the negative effects that could result from techniques such as SCNT. 
However, it was noted that there were differences between natural stem cells and 
the iPSCs. The scientists from Japan attributed those changes to intrinsic factors that were 
already present in the adult cells before the viral DNA was added. The following Embryo 
Project Encyclopedia article details the iPSC experiments.  
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Induced Pluripotent Stem Cell Experiments by Kazutoshi Takahashi and Shinya 
Yamanaka in 2006 and 2007  
 
Bartlett, Zane, "Induced Pluripotent Stem Cell Experiments by Kazutoshi Takahashi and Shinya Yamanaka 
in 2006 and 2007". Embryo Project Encyclopedia (2015-06-01). ISSN: 1940-5030 
http://embryo.asu.edu/handle/10776/8325. 
In 2006, Kazutoshi Takahashi and Shinya Yamanaka reprogrammed mice 
fibroblast cells, which can produce only other fibroblast cells, to become pluripotent stem 
cells, which have the capacity to produce many different types of cells. Takahashi and 
Yamanaka also experimented with human cell cultures in 2007. Each worked at Kyoto 
University in Kyoto, Japan. They called the pluripotent stem cells that they 
produced induced pluripotent stem cells (iPSCs) because they had induced the adult cells, 
called differentiated cells, to become pluripotent stem cells through genetic manipulation. 
Yamanaka received the Nobel Prize in Physiology or Medicine in 2012, along with John 
Gurdon, as their work showed scientists how to reprogram mature cells to become 
pluripotent. Takahashi and Yamanaka's 2006 and 2007 experiments showed that 
scientists can prompt adult body cells to dedifferentiate, or lose specialized 
characteristics, and behave similarly to embryonic stem cells (ESCs). 
Takahashi and Yamanaka worked together at Kyoto University. Takahashi was a 
post-doctoral researcher who had earned a graduate degree in biology at the Nara 
Institute of Science and Technology in Ikoma, Japan. Yamanaka had earned an MD from 
Kobe University in Kobe, Japan in 1987. In 2004, Yamanaka began working at Kyoto 
University as a professor, where he studied factors that help an organism fend off 
retroviruses, which are single-stranded RNA viruses that can incorporate their genetic 
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material into the DNA of a host cell. Yamanaka and others hypothesized that retroviruses 
could influence somatic cells to become stem cells. Yamanaka worked to find new ways 
to acquire embryonic stem cells to avoid the social and ethical controversies surrounding 
the use of human embryos in stem cell research during the late twentieth and early 
twenty-first centuries. Yamanaka studied the work of John Gurdon, a researcher who had 
experimented with Xenopus frogs at the University of Oxford in Oxford, United 
Kingdom. Yamanaka claimed that Gurdon's work in reprogramming mature cells in frogs 
(Xenopus) in 1962 influenced his own work in reprogramming differentiated cells. 
Yamanaka also noted that experiments in cloning Dolly the sheep in 1996, 
conducted by Ian Wilmut, Angelica Schnieke, Jim McWhir, Alex Kind, and Keith 
Campbell at the Roslin Institute in Roslin, Scotland, influenced his work. The Dolly 
experiment showed that scientists could reprogram the nucleus of somatic cells by 
transferring the contents of the nucleus into oocytes that have had their nuclei removed, a 
technique called somatic cell nuclear transfer (SCNT). Other research groups such as 
Masako Tada's group in Japan in 2001 and Chad Cowan’s group in Massachusetts in 
2005 combined embryonic stem cells with somatic cells to produce pluripotent cells. 
After these experiments with somatic cells, Takahashi and Yamanaka hypothesized that 
there were common factors, genes in particular, which caused somatic cells to become 
pluripotent stem cells. 
In 2006, Takahashi and Yamanaka selected twenty-four candidate genes as 
factors that they hypothesized could possibly induce somatic cells to become pluripotent, 
and they began to test them one at a time. They used retroviruses to insert each of the 
twenty-four genes into the chromosomes of differentiated mouse embryonic fibroblasts. 
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Each gene was inserted near the mouse Fbx15 gene, a gene that embryonic stem 
cells express during development in mice. The newly inserted gene endowed mice with 
resistance to an antibiotic named G418. The researchers labeled the resulting retroviruses 
mixed with host DNA as retroviral factors. Takahashi and Yamanaka placed 
the retrovirus-infected cells into cell culture with G418 antibiotic and cells to provide 
nourishment, called feeder cells. If one of the infected cells showed G418 resistance, then 
the scientists would know that one of the twenty-four genes influenced the cell to become 
an embryonic stem cell-like cell. However, none of the cells showed a resistance to 
G418, so Takahashi and Yamanaka reworked their approach. 
Next, Takahashi tried to insert into a fibroblast cell multiple retroviral 
factors instead of one at a time. The researchers added all of the twenty-four retroviral 
factors at the same time into mouse fibroblast cells. This time, there were twenty-two cell 
colonies that showed a resistance to G418, meaning that there were colonies in which the 
cells exhibited embryonic stem cell properties. After examination, Takahashi and 
Yamanaka concluded that the cells were similar to embryonic stem cells and duplicated 
themselves in similar periods of as embryonic stem cells. They named the cells iPS-
MEF24, signifying pluripotent stem cells induced from mouse embryonic fibroblasts by 
twenty-four factors. 
The next experiments aimed to identify specific factors responsible for the 
generation of iPS cells. To isolate these specific factors, the researchers 
removed retroviral factors one at a time from the original twenty-four, and each time they 
removed a factor, they repeated their cell colony procedures. If the researchers removed a 
factor and the resultant cell colony wasn't resistant to antibiotics, they knew that the 
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missing factor somehow influenced the generation of iPS cells. Takahashi and Yamanaka 
repeated their procedure until they found ten genes that, when combined together in cells, 
yielded colonies of cells with G418 resistance. They named those cells with the 
ten genes as iPS-MEF10 cells. Takahashi and Yamanaka found that of the ten genes, 
when they combined four genes in particular (Oct3/4, KIf4, Sox2, and c-Myc), they 
produced the most cells that were like embryonic stem cells. The scientists named the 
cells iPS-MEF4. Takahashi and Yamanaka deemed those four genes important in the role 
of iPS cell generation. They concluded that iPSCs are similar, but not identical 
to embryonic stem cells. 
To determine how embryonic stem cells were different from iPSCs, Takahashi 
and Yamanaka used primers, or strands of nucleic acid that help to start the process of 
DNA synthesis, to promote replication of genes found in normal embryonic stem cells. If 
an iPSC had a normal embryonic stem cell gene, the primer would prompt the normal 
gene to replicate, and the scientists could then see that the iPSC had a normal gene. 
Takahashi and Yamanaka continued their experiments and injected the iPSC 
samples into mice that had no body hair. These nude mice were a variation of the 
common mouse (Mus musculus), but they had an inhibited immune system and lacked 
the Fox1 gene. When the researchers injected iPSCs into the mice, teratomas, which are 
tumors with germ layer components, formed. The teratomas resulting from iPS-MEF4 
injections differentiated into all three germ layers (ectoderm, endoderm, and mesoderm), 
including neural and muscular tissues, cartilage, and epithelium. These tissue types 
formed aggregates of pluripotent stem cells called embryoid bodies. From the teratomas, 
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Takahashi and Yamanaka took some cell samples and cloned them. They inserted the 
cloned cells into blastocysts by microinjection and obtained four different embryos. 
After analysis, Yamanaka and Takahashi found that the four embryos contained 
iPS cells that contributed to all three germ layers, providing further evidence that the 
four genes (Oct3/4, KIf4, Sox2, and c-Myc) helped produce cells that were the most 
like embryonic stem cells. Takahashi and Yamanaka observed that the iPS-MEF4 cells 
continued to be more similar to embryonic stem cells than to other iPS cells. After further 
experimentation, they concluded that the iPS cells they generated were pluripotent in 
mice, and therefore provided the possibly of repeating a similar experiment in humans. 
Takashi and Yamanaka published the results of their experiment in 2006. 
After their mouse experiments, in 2007 Takahashi and Yamanaka published the 
results of another experiment that detailed methods and results used to produce iPS cells 
with human cells. They used the same four genes from humans that were used in mice. 
Another group led by James Thomson at the University of Wisconsin in Madison, 
Wisconsin, published their findings on iPSC in humans. They found that four genes–
Oct4, Sox2, NanoG, and Lin28–were sufficient to reprogram human somatic cells into 
pluripotent stem cells. Independent confirmation of Takahashi and Yamanaka's previous 
experiments with mice supported the hypothesis that scientists can generate and 
use induced pluripotent stem cells in a similar manner as embryonic stem cells. Scientists 
later used iPSCs in regenerative medicine to research treatments for various human 
diseases such as Parkinson's disease, platelet deficiency, spinal cord injury, and macular 
degeneration. 
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In June 2012, Yamanaka reported that experiments showed many epigenetic 
differences, as well as gene expression differences, between iPSCs and embryonic stem 
cells. Yamanaka cited as an example the chemical addition of methyl groups 
(methylation) of the gene that makes bone morphogenic protein 3 (BMP3), which partly 
causes bone and cartilage development in humans. He also mentioned that there are other 
examples of high amounts of variation and mutations in iPSCs, which alarmed some 
scientists. Yamanaka said that many of the variations in the genes and epigenetics are 
likely from the original somatic cell from which the iPSCs are descended, and that the 
negative reports on iPSCs were often overstated. 
In 2012, Yamanaka and John Gurdon received the Nobel Prize in Physiology or 
Medicine their discovery that differentiated cells can be reprogrammed to become 
pluripotent. The Nobel Prize committee stated that Takahashi and Yamanaka's 
experiments with mice iPSCs contributed to Yamanaka's award. Scientists in the second 
decade of the twenty-first century experimented with iPSCs to generate cells similar 
to embryonic stem cells without destroying or manipulating embryos. 
Cowan, Chad A., Jocelyn Atienza, Douglas A. Melton, and Kevin Eggan. 
"Nuclear reprogramming of somatic cells after fusion with human embryonic 
stem cells." Science 309 (2005): 1369–73. 
 
Fackler, Martin. "Risk taking is in his genes." New York Times, December 11, 
2007, Science 
Section. http://www.nytimes.com/2007/12/11/science/11prof.html (Accessed 
April 6, 2014). 
 
Gurdon, John B. "The transplantation of nuclei Between two species of 
Xenopus." Developmental Biology 5 (1962): 68–83. 
 
Gurdon, John B. "Adult frogs derived from the nuclei of single somatic 
cells." Developmental Biology 4 (1962): 256–73. 
  114 
Maienschein, Jane. Embryos Under the Microscope: The Diverging Meanings of 
Life. Cambridge, MA: Harvard University Press, 2014. 
 
Nobel Media. "The Nobel Prize in Physiology or Medicine 2012". 
Nobelprize.org. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/
 (Accessed April 6, 2014). 
 
Tada, Masako, Yousuke Takahama, Kuniya Abe, Norio Nakatsuji, and Takashi 
Tada. "Nuclear reprogramming of somatic cells by in vitro hybridization with ES 
cells." Current Biology 11 (2001): 1553–8. http://dx.doi.org/10.1016/S0960-
9822(01)00459-6 (Accessed May 5, 2015). 
 
Takahashi, Kazutoshi, Koji Tanabe, Mari Ohnuki, Megumi Narita, Tomoko 
Ichisaka, Kiichiro Tomoda, and Shinya Yamanaka. "Induction of pluripotent stem 
cells from adult human fibroblasts by defined factors." Cell 131 (2007): 861–
72. http://dx.doi.org/10.1016/j.cell.2007.11.019 (Accessed May 5, 2015). 
 
Takahashi, Kazutoshi, and Shinya Yamanaka. "Induction of pluripotent stem 
cells from mouse embryonic and adult fibroblast cultures by defined 
factors." Cell 126 (2006): 663–
76. http://dx.doi.org/10.1016/j.cell.2006.07.024 (Accessed May 5, 2015). 
 
Wilmut, Ian, Angelica E. Schnieke, Jim McWhir, Alex J. Kind, and Keith H. S. 
Campbell. "Viable offspring derived from fetal and adult mammalian 
cells." Nature 385 (1997): 810–3. 
 
Yamanaka, Shinya. "Induced pluripotent stem cells: past, present, and 
future." Cell Stem Cell 10 (2012): 678–
84. http://dx.doi.org/10.1016/j.stem.2012.05.005 (Accessed May 5, 2015). 
 
Yu, Junying, Maxim A. Vodyanik, Kim Smuga-Otto, Jessica Antosiewicz-
Bourget, Jennifer L. Frane, Shulan Tian, Jeff Nie, Gudrun A. Jonsdottir, Victor 
Ruotti, Ron Stewart, Igor I. Slukvin, and James A. Thomson. "Induced pluripotent 
stem cell lines derived from human somatic cells." Science 318 (2007): 1917–20. 
 
  115 
CHAPTER 6 
CONCLUSION 
This cluster of articles from the Embryo Project Encyclopedia makes clear that 
there are a wide variety of methods of obtaining and culturing immortal cell lines. 
Modern methods borrow from practices and theories of scientists in the past, which was 
particularly evident in chapter 2 of this thesis. For example, scientists culture hESCs in a 
strikingly similar fashion as Alexis Carrel cultured the cells in his chick heart 
experiments: with the use of proper nutrients, skillful technicians, and meticulous 
selection of petri dishes. For the proper nutrients, scientists place embryonic cells of mice 
in petri dishes for hESCs to feed on. It is rare for hESCs to retain their pluripotency by 
using any other feeder cells. Though some researchers use human foreskin cells as feeder 
cells, the most common practice currently is to use mouse embryonic cells. If hESCs fail 
to retain their pluripotency through prolonged culturing, scientists often attribute the 
resulting senescence to external factors such as a lack of proper feeder cells, the shape of 
the petri dish, or incorrect laboratory methods.  
Recent research suggests that hESCs, and immortalized cell lines in general, do 
not escape the effects of senescence. As was discussed in the Embryo Project 
Encyclopedia articles of chapter 3, much of the research on immortalized cell lines and 
senescence examines the function of telomeres and telomerase, which the majority of 
scientists use as the deciding factor to determine whether a cell is viable and will 
continue to replicate. 
However, there is conflicting research among scientists over other factors besides 
telomeres and telomerase that contribute to senescence. For example, the human cell 
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organelle, the mitochondria, has DNA apart from the chromosome of the cell. Mutations 
can occur in human mitochondrial DNA (mtDNA), independently of nuclear DNA, 
which leads to dysfunctional cell metabolism and cessation of indefinite cellular 
replication, or a loss of immortality. Some suggest that hESCs do not appear to have 
mitochondrial defects, though other scientists claim there are defects (Bernardo).  
SCNT could provide a possible method of testing whether mitochondrial defects 
influence senescence in immortal cell lines. A nucleus from an immortalized cell with 
notably lengthy telomeres, and high expression of telomerase could be transferred over to 
an enucleated cell that contains normal or mutated mitochondria. Scientists could also 
take existing immortal cell lines and perform SCNT to potentially mitigate mitochondrial 
defects in future cell generations. Conversely, articles from the Embryo Project 
Encyclopedia as described in chapters 4 and 5 suggest that SCNT is not a perfect 
technique. An alternative method such as the method used to produce iPSCs could be 
used to determine if there is a relationship between mitochondrial defects and senescence. 
As was discussed in chapter 5, iPSCs have epigenetic differences when compared 
to natural pluripotent stem cells. Scientists also claim epigenetics can influence 
senescence. Epigenetics refer to heritable characteristics of genes, which do not directly 
involve changes to the DNA of an organism. An example of an epigenetic effect includes 
methylation of protein structures that coat DNA strands. An increase or decrease in 
methylation can cause a cell to produce more or less of a protein. In the case of iPSCs, 
Yamanaka claims epigenetic differences exist because of factors already present in the 
adult cells (Yamanaka). Further research is needed to understand the relationship between 
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selection of adult cells and the resulting epigenetic changes in iPSCs derived from those 
adult cells, as well as hESCs and other immortal cell lines.  
Aside from epigenetic changes, there is evidence to suggest there are also direct 
genetic changes that occur in immortal cell lines over prolonged periods of cell culturing. 
In the journal Nature biotechnology in 2007, researchers in the United Kingdom reported 
that they observed chromosomal abnormalities in hESCs that had been cultured using 
mass production techniques in as little as 23 passages. In hESC cultures that were 
produced manually, they noted chromosomal abnormalities after about 105 passages. As 
the most common changes, they noted gains in chromosomes 1, 7, 12, 17, and x, with the 
gain in chromosome 17 as the most prominent (Baker). The researchers also reported 
chromosomal loss in chromosome 13. They suggest that those chromosomal changes lead 
to increasingly malignant cell cultures, and they attribute the cause of the chromosomal 
changes to selective pressures that occur when cells move from one environment to 
another, or from culture dish to culture dish. The scientists propose that more research is 
needed to find methods to adapt hESCs to culturing. 
As a final inclusion to the contributing factors of senescence already mentioned, 
there are some studies that point to the idea that cells go through senescence independent 
of telomere shortening due to the generally vague term, “stress” (Campisi). Such stressors 
are of unknown causes, though the result of those stressors can be replicative senescence. 
As was the case in Leonard Hayflick’s day, further research is needed to properly address 
the issue of senescence in cell lines that were once thought of and cultured as immortal. 
In addition to gleaning from past practices, researchers continue to conduct 
experiments with cell populations established before modern understanding of 
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senescence and cell biology. The most prominent immortal cell line being HeLa cells, 
which have been in use since 1951. HeLa cells also account for contamination in 27 of 93 
cell culture suppliers, and are therefore contributing to studies that were not originally 
designed to use HeLa cells (Lucey). Questions arise as to the efficacy of repeatedly 
culturing an immortalized cell line such as HeLa. What might be some of the changes 
that occur in a cell line in the course of 64 years? If there are changes in those cell lines, 
are researchers giving proper attention to said changes?  
 In the case of hESCs, due to recent regulatory changes in the United States, only 
a select number of hESC lines are available for experimentation (NIH). Those limitations 
could be encouraging repeated use of already approved immortal cell lines that contain 
abnormalities. Some scientists may not even realize they are conducting experiments with 
cell lines that are distinctly different from natural cells. With the help of modern 
understanding of cell biology and senescence, scientists should investigate currently 
approved immortal cell lines and screen those lines for existing abnormalities.  
While there exists a constant change in the practices of cell culturing, a large 
portion of scientists still rely on practices established before modern senescence research: 
research that seems to suggest that cultured hESCs, among other immortal cell lines, are 
not truly immortal. Though scientists are encouraged to present many solutions to the 
challenges of culturing immortal cell lines, this thesis proposes the following solutions: 
 
1) Examine all known facets of senescence. Telomeres and telomerase are only one of 
many contributing causes of aging in cells. There is a need for more research 
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pertaining to those other contributing factors, particularly unknown causes of 
stressors and nutrients needed for immortal cell lines. 
2) Renew populations. Though currently ethically perilous in the United States (which 
can be a thesis entirely in itself), scientists could retrieve fresh stem cells, as opposed 
to perpetually culturing aged cells. Such a practice would reduce chromosomal 
abnormalities. The length of time required before cell renewal warrants further 
research. 
3) Select for healthy populations of immortalized cells. Continued selection may 
produce an immortalized cell line that is adapted to prolonged cell culturing. 
Selection techniques would need to be developed. 
4) Reduce factors of senescence in the cell. Scientists could use SCNT to replace 
damaged mtDNA. IPSCs may reduce the cytoplasmic damage caused from SCNT, 
though IPSCs have epigenetic differences. There are likely many other ways to 
reduce other factors of senescence that need scientific attention. 
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